#civic-chromosome	civic-start	civic-stop	civic-reference_bases	civic-variant_bases	civic-gene	civic-variant	civic-variant_civic_url:civic-rating:civic-evidence_level:civic-disease:civic-drugs:civic-evidence_type:civic-evidence_direction:civic-clinical_significance:civic-variant_origin
1	8073509	8073509	C	A	ERRFI1	E384*	691:2:C:Cholangiocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	11177096	11177096	C	A	MTOR	M2327I	609:3:D:Breast Cancer:RapaLink-1,Rapamycin (Sirolimus):Predictive:Does Not Support:Resistance:Somatic Mutation|609:4:D:Breast Cancer:AZD8055:Predictive:Supports:Resistance:Somatic Mutation
1	11184573	11184573	G	T	MTOR	S2215Y	542:2:D:Endometrial Adenocarcinoma:Rapamycin (Sirolimus):Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	11184580	11184580	G	A	MTOR	P2213S	284:3:D:Melanoma:LY294002,AZD5363:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	11187094	11187094	G	T	MTOR	F2108L	470:4:D:Breast Cancer:Rapamycin (Sirolimus):Predictive:Supports:Resistance:Somatic Mutation|470:5:C:Thyroid Carcinoma:Everolimus:Predictive:Supports:Resistance:Somatic Mutation
1	11187796	11187796	G	A	MTOR	A2034V	610:4:D:Breast Cancer:Rapamycin (Sirolimus):Predictive:Supports:Resistance:Somatic Mutation|610:4:D:Breast Cancer:AZD8055,RapaLink-1:Predictive:Does Not Support:Resistance:Somatic Mutation
1	11188519	11188519	G	A	MTOR	H1968Y	283:3:D:Melanoma:LY294002,AZD5363:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	11190804	11190804	C	T	MTOR	E1799K	544:2:D:Clear Cell Renal Cell Carcinoma:Rapamycin (Sirolimus):Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	11217230	11217230	C	T	MTOR	C1483Y	543:2:D:T-cell Acute Lymphoblastic Leukemia:Rapamycin (Sirolimus):Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	11856378	11856378	G	A	MTHFR	A222V	258:3:B:Stomach Cancer:5-fluorouracil:Predictive:Supports:Sensitivity/Response:Germline Mutation|258:4:B:Rectum Cancer:5-fluorouracil:Predictive:Supports:Sensitivity/Response:Germline Polymorphism|258:4:B:Pancreatic Cancer::Prognostic:Supports:Better Outcome:Germline Mutation
1	65311203	65311203	C	A	JAK1	S703I	822:4:D:Hepatocellular Carcinoma:Ruxolitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	65321333	65321333	G	A	JAK1	Q503*	614:4:C:Skin Melanoma:Pembrolizumab:Predictive:Supports:Resistance:Somatic Mutation
1	68152388	68152388	T	C	GADD45A	rs681673	705:3:B:Ovarian Cancer::Predisposing:Supports:Positive:Germline Polymorphism
1	97915614	97915614	C	T	DPYD	DPYD*2A HOMOZYGOSITY	737:5:A:Cancer:5-FU,Tegafur,Capecitabine:Predictive:Supports:Adverse Response:Germline Polymorphism
1	97981343	97981343	A	C	DPYD	DPYD*13 HOMOZYGOSITY	738:5:A:Cancer:5-FU,Capecitabine,Tegafur:Predictive:Supports:Adverse Response:Germline Polymorphism
1	115256529	115256529	T	A	NRAS	Q61L	95:2:C:Melanoma:Temozolomide:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	115256529	115256529	T	C	NRAS	Q61R	96:2:C:Melanoma:Temozolomide:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	115256530	115256530	G	T	NRAS	Q61K	427:2:D:Non-small Cell Lung Carcinoma:Trametinib,Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Somatic Mutation|427:2:D:Skin Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|427:2:D:Skin Melanoma:Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Somatic Mutation|427:3:D:Colorectal Cancer:Selumetinib (AZD6244),BEZ235:Predictive:Supports:Sensitivity/Response:Somatic Mutation|427:3:D:Neuroblastoma:Everolimus,Binimetinib (MEK162):Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	115258744	115258744	C	T	NRAS	G13D	93:2:C:Melanoma:17-AAG:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	115258747	115258747	C	T	NRAS	G12D	878:0:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
1	161479745	161479745	A	G	FCGR2A	H167R	456:3:B:Breast Cancer::Prognostic:Does Not Support:N/A:Germline Polymorphism|456:4:B:Breast Cancer::Prognostic:Does Not Support:N/A:Germline Polymorphism
1	161514542	161514542	A	C	FCGR3A	F212V	457:3:B:Breast Cancer::Prognostic:Does Not Support:N/A:Germline Polymorphism|457:4:B:Breast Cancer:Trastuzumab:Predictive:Does Not Support:N/A:Germline Polymorphism
1	161643798	161643798	T	C	FCGR2B	I232T	458:4:B:Breast Cancer::Prognostic:Supports:Poor Outcome:Germline Polymorphism
1	162724415	162724415	C	G	DDR2	L63V	139:4:D:Non-small Cell Lung Carcinoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	162729630	162729630	T	G	DDR2	L239R	140:4:D:Non-small Cell Lung Carcinoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	162729671	162729671	G	T	DDR2	G253C	141:4:D:Non-small Cell Lung Carcinoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	162741822	162741822	G	A	DDR2	G505S	142:4:D:Non-small Cell Lung Carcinoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	162745497	162745497	A	T	DDR2	I638F	143:4:D:Non-small Cell Lung Carcinoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	162748390	162748390	T	A	DDR2	S768R	145:3:C:Non-small Cell Lung Carcinoma:Dasatinib,Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	162748407	162748407	G	T	DDR2	G774V	144:4:D:Non-small Cell Lung Carcinoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
1	243859016	243859016	C	T	AKT3	E17K	1227:3:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation
2	29432664	29432664	C	T	ALK	R1275Q	9:2:C:Neuroblastoma:Crizotinib:Predictive:Supports:Sensitivity/Response:Germline Mutation|9:2:C:Neuroblastoma:Crizotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|9:3:D:Neuroblastoma:TAE684:Predictive:Supports:Resistance:Somatic Mutation|9:3:D:Neuroblastoma:Crizotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|9:3:D:Neuroblastoma:TAE684:Predictive:Supports:Sensitivity/Response:Somatic Mutation|9:4:D:Neuroblastoma:Lorlatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	29432682	29432682	C	G	ALK	ALK FUSION G1269A	552:2:D:Cancer:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|552:2:D:Cancer:Brigatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|552:3:D:Cancer:Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation|552:3:D:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	29432682	29432682	C	G	ALK	EML4-ALK G1269A	308:3:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|308:4:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
2	29436859	29436859	A	C	ALK	ALK FUSION F1245C	551:2:D:Cancer:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|551:2:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|551:3:C:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	29436859	29436859	A	C	ALK	F1245C	549:3:C:Neuroblastoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|549:3:D:Neuroblastoma:Lorlatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	29443600	29443600	G	T	ALK	EML4-ALK S1206Y	172:2:D:Cancer:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|172:4:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
2	29443613	29443613	C	T	ALK	ALK FUSION G1202R	171:2:D:Non-small Cell Lung Carcinoma:17-AAG:Predictive:Supports:Sensitivity/Response:Somatic Mutation|171:3:D:Cancer:Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation|171:3:C:Lung Adenocarcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|171:3:D:Cancer:Brigatinib:Predictive:Supports:Resistance:Somatic Mutation|171:4:D:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Resistance:Somatic Mutation|171:4:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
2	29443631	29443631	G	T	ALK	EML4-ALK L1196M	7:3:D:Non-small Cell Lung Carcinoma:Alectinib (CH5424802):Predictive:Supports:Sensitivity/Response:Somatic Mutation|7:4:D:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|7:4:B:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|7:4:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
2	29443679	29443679	C	G	ALK	EML4-ALK  V1180L	528:2:D:Non-small Cell Lung Carcinoma:Brigatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|528:2:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|528:3:D:Non-small Cell Lung Carcinoma:Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation|528:3:D:Non-small Cell Lung Carcinoma:TAE684:Predictive:Supports:Sensitivity/Response:Somatic Mutation|528:3:D:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	29443695	29443695	G	T	ALK	F1174L	8:3:C:Neuroblastoma:Crizotinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|8:3:D:Neuroblastoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|8:3:D:Neuroblastoma:AZD3463:Predictive:Supports:Sensitivity/Response:Somatic Mutation|8:3:D:Neuroblastoma:Alectinib (CH5424802):Predictive:Supports:Sensitivity/Response:Somatic Mutation|8:3:D:Inflammatory Myofibroblastic Tumor:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|8:3:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|8:3:D:Neuroblastoma:Crizotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|8:4:D:Neuroblastoma:Lorlatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|8:4:D:Neuroblastoma:TAE684:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	29445213	29445213	A	C	ALK	EML4-ALK I1171S	589:2:C:Non-small Cell Lung Carcinoma:Crizotinib,Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation
2	29445213	29445213	A	G	ALK	ALK FUSION I1171	527:2:C:Non-small Cell Lung Carcinoma:Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation|527:3:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|527:3:C:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|527:3:D:Non-small Cell Lung Carcinoma:TAE684:Predictive:Supports:Sensitivity/Response:Somatic Mutation|527:4:D:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|527:4:C:Non-small Cell Lung Carcinoma:Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation|527:4:C:Non-small Cell Lung Carcinoma:Ceritinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	29445213	29445213	A	T	ALK	HIP1-ALK I1171N	588:2:C:Non-small Cell Lung Carcinoma:Crizotinib,Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation
2	29445258	29445258	C	T	ALK	EML4-ALK C1156Y	6:3:C:Non-small Cell Lung Carcinoma:Crizotinib,AUY922,Ceritinib:Predictive:Supports:Resistance:Somatic Mutation|6:3:C:Non-small Cell Lung Carcinoma:Lorlatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|6:4:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
2	29445270	29445270	A	C	ALK	EML4-ALK L1152R	307:4:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
2	29445271	29445271	-	CGT	ALK	EML4-ALK T1151INST	173:2:D:Non-small Cell Lung Carcinoma:17-AAG:Predictive:Supports:Sensitivity/Response:Somatic Mutation|173:3:D:Non-small Cell Lung Carcinoma:TAE684:Predictive:Supports:Resistance:Somatic Mutation|173:3:D:Non-small Cell Lung Carcinoma:Alectinib (CH5424802):Predictive:Supports:Resistance:Somatic Mutation|173:4:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
2	47630413	47630413	-	G	MSH2	E28FS	763:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	47637380	47637380	A	T	MSH2	K172*	770:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	47641433	47641433	T	-	MSH2	V273FS	762:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	47656951	47656951	C	T	MSH2	R383*	727:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	47690231	47690231	A	G	MSH2	E483G	773:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	48018217	48018217	C	A	MSH6	P138T	761:1:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	48026176	48026176	G	A	MSH6	V352I	775:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	48027794	48027795	TC	-	MSH6	I891FS	765:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	48033420	48033420	C	T	MSH6	R1242C	776:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	48033421	48033421	G	A	MSH6	R1242H	767:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
2	158622516	158622516	C	A	ACVR1	G328V	1686:3:B:Diffuse Intrinsic Pontine Glioma::Diagnostic:Supports:Positive:Somatic Mutation
2	198266834	198266834	T	C	SF3B1	K700E	565:2:D:Breast Cancer:Spliceostatin A:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	198267359	198267359	C	A	SF3B1	K666N	114:2:D:Breast Cancer:Spliceostatin A:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	202149589	202149589	G	C	CASP8	D302H	650:3:B:Neuroblastoma::Prognostic:Supports:Poor Outcome:Germline Polymorphism
2	209113112	209113112	C	A	IDH1	R132L	880:2:B:Malignant Glioma:Bevacizumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	209113112	209113112	C	T	IDH1	R132H	420:2:C:Pancreatic Ductal Adenocarcinoma:AG-120:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|420:4:D:Anaplastic Oligodendroglioma:AGI-5198:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	209113113	209113113	G	A	IDH1	R132C	59:0:B:Glioblastoma Multiforme:Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|59:2:B:Acute Myeloid Leukemia::Prognostic:Does Not Support:N/A:Somatic Mutation|59:2:B:Acute Myeloid Leukemia:AG-120:Predictive:Supports:Sensitivity/Response:Somatic Mutation|59:2:B:Malignant Glioma:Bevacizumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|59:2:B:Brain Glioma:Temozolomide:Predictive:Supports:Sensitivity/Response:Somatic Mutation|59:2:D:Malignant Glioma:AGI-5198:Predictive:Supports:Sensitivity/Response:Somatic Mutation|59:3:D:Acute Myeloid Leukemia:Bis-2-[5-(phenylacetamide)-1,3,4-thiadiazol-2-yl]ethyl Sulfide:Predictive:Supports:Sensitivity/Response:Somatic Mutation|59:3:B:Acute Myeloid Leukemia::Diagnostic:Supports:Positive:Somatic Mutation|59:3:D:Acute Myeloid Leukemia:GSK321:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	209113113	209113113	G	T	IDH1	R132S	928:2:B:Malignant Glioma:Bevacizumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation
2	234668881	234668881	-	TATATATATATATA	UGT1A1	UGT1A1*28	729:5:A:Cancer:Belinostat:Predictive:Supports:Adverse Response:Germline Polymorphism
3	10183531	10183551	AATGCCCCGGAGGGCGGAGAA	-	VHL	M1? (c.1-1_20del21)	847:2:E:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	10183532	10183548	ATGCCCCGGAGGGCGGA	-	VHL	M1FS (c.1_17del17)	846:2:E:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	10183534	10183534	G	A	VHL	M1? (c.3G>A)	848:2:E:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	10183550	10183550	A	G	VHL	N7D (c.19A>G)	849:1:E:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	10183605	10183605	C	T	VHL	P25L (c.74C>T)	850:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183667	10183667	G	T	VHL	E46* (c.136G>T)	1733:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Likely Pathogenic:Germline Mutation
3	10183685	10183685	G	A	VHL	E52K (c.154G>A)	1734:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183693	10183697	GGAGG	-	VHL	M54IFS (c.162_166delGGAGG)	829:2:E:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	10183694	10183694	G	-	VHL	E55RfsTer11 (c.163delG)	766:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183694	10183695	GA	-	VHL	E55FS (c.163_164delGA)	764:2:E:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	10183695	10183695	-	A	VHL	A56FS (c.164_165insA)	793:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183695	10183695	-	G	VHL	A56FS (c.164_165insG)	771:4:B:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183696	10183696	G	A	VHL	E55E (c.165G>A)	794:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183704	10183704	-	C	VHL	P59fs (c.173_174insC)	851:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183706	10183706	C	-	VHL	P59R (c.175delC)	1786:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183710	10183710	G	-	VHL	R60FS (c.179delG)	1964:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183711	10183711	G	-	VHL	V62C (c.180delG)	1750:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183713	10183716	CCGT	-	VHL	P61FS (c.182_185delCCGT)	2145:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183722	10183722	G	C	VHL	R64P (c.191G>C)	1867:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183724	10183724	T	C	VHL	S65P (c.193T>C)	1903:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183724	10183724	T	G	VHL	S65A (c.193T>G)	2011:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183725	10183725	C	-	VHL	S65FS (c.194delC)	2130:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183725	10183725	C	A	VHL	S65* (c.194C>A)	1811:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183725	10183725	C	G	VHL	S65W (c.194C>G)	1787:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1787:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183725	10183725	C	T	VHL	S65L (c.194C>T)	1788:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Unknown|1788:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1788:2:E:Clear Cell Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Somatic Mutation|1788:3:C:Renal Carcinoma::Predisposing:Supports:Uncertain Significance:Somatic Mutation|1788:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183733	10183733	T	C	VHL	S68P (c.202T>C)	1873:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183739	10183739	G	A	VHL	E70K (c.208G>A)	1956:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1956:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1956:3:C:Von Hippel-Lindau Disease::Diagnostic:Supports:Positive:Germline Mutation
3	10183739	10183739	G	T	VHL	E70* (c.208G>T)	1834:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1834:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1834:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:N/A
3	10183745	10183745	T	-	VHL	S72P (c.214delT)	1816:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183745	10183745	T	C	VHL	S72P (c.214T>C)	1904:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183748	10183748	C	-	VHL	Q73fs (c.217delC)	2041:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183748	10183748	C	T	VHL	Q73* (c.217C>T)	1752:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1752:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183752	10183752	T	G	VHL	V74G (c.221T>G)	1999:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183754	10183754	-	T	VHL	F76fs (c.223_224insT)	1912:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183757	10183759	TTC	-	VHL	F76del (c.226_228delTTC)	2015:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|2015:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|2015:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183758	10183758	T	C	VHL	F76S (c.227T>C)	1835:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183758	10183760	TCT	-	VHL	F76del (c.227_229delTCT)	1926:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1926:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1926:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1926:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183759	10183759	-	C	VHL	C77FS (c.228_229insC)	1790:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183763	10183763	A	C	VHL	N78H (c.232A>C)	1754:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1754:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1754:4:C:Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Germline Mutation|1754:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183764	10183764	A	C	VHL	N78T (c.233A>C)	1756:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183764	10183764	A	G	VHL	N78S (c.233A>G)	1755:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1755:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1755:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183764	10183764	A	T	VHL	N78I (c.233A>T)	2037:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183767	10183767	G	C	VHL	R79P (c.236G>C)	1791:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183769	10183769	A	C	VHL	S80R (c.238A>C)	1963:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183770	10183770	G	A	VHL	S80N (c.239G>A)	1874:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1874:2:C:Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Germline Mutation|1874:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1874:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183770	10183770	G	T	VHL	S80I (c.239G>T)	1757:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1757:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183771	10183771	T	G	VHL	S80R (c.240T>G)	1792:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1792:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183772	10183772	C	T	VHL	P81S (c.241C>T)	1837:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183775	10183783	CGCGTCGTG	-	VHL	R82_V84del (c.244_252del)	2264:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:N/A
3	10183781	10183781	G	T	VHL	V84L (c.250G>T)	1815:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183785	10183785	T	C	VHL	L85P (c.254T>C)	2020:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183787	10183787	C	G	VHL	P86A (c.256C>G)	1759:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183787	10183787	C	T	VHL	P86S (c.256C>T)	1902:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1902:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1902:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183788	10183788	C	G	VHL	P86R (c.257C>G)	1849:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1849:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183788	10183788	C	T	VHL	P86L (c.257C>T)	1760:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183793	10183793	T	A	VHL	W88R (c.262T>A)	1761:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1761:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183793	10183793	T	C	VHL	W88R (c.262T>C)	2056:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183794	10183794	G	A	VHL	W88* (c.263G>A)	2151:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183794	10183794	G	C	VHL	W88S (c.263G>C)	1966:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183794	10183796	GGC	TT	VHL	W88fs (c.263_265delGGCinsTT)	2039:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183795	10183795	G	A	VHL	W88* (c.264G>A)	1908:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183797	10183797	T	C	VHL	L89P (c.266T>C)	1793:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1793:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1793:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183808	10183808	G	A	VHL	G93S (c.277G>A)	1859:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1859:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183808	10183808	G	C	VHL	G93R (c.277G>C)	1920:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183808	10183808	G	T	VHL	G93C (c.277G>T)	2008:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183809	10183809	G	T	VHL	G93V (c.278G>T)	2009:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183811	10183811	G	T	VHL	E94* (c.280G>T)	1794:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1794:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1794:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183817	10183817	C	T	VHL	Q96* (c.286C>T)	1848:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183822	10183822	C	-	VHL	Y98FS (c.291delC)	2160:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183822	10183841	CTACCCAACGCTGCCGCCTG	-	VHL	Y98FS (c.291_310del20)	852:2:E:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	10183823	10183823	T	C	VHL	Y98H (c.292T>C)	1741:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1741:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation|1741:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183824	10183824	A	G	VHL	Y98C  (c.293A>G)	1933:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183836	10183836	C	-	VHL	P102fs (c.305delC)	2058:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183840	10183841	TG	-	VHL	P103FS (c.309_310delTG)	1795:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183844	10183844	A	C	VHL	T105P (c.313A>C)	1839:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1839:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183850	10183850	C	G	VHL	R107G  (c.319C>G)	2007:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183851	10183851	G	C	VHL	R107P (c.320G>C)	1840:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183863	10183863	G	A	VHL	S111N (c.332G>A)	1763:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1763:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183864	10183864	C	G	VHL	S111R (c.333C>G)	1764:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1764:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183865	10183865	T	C	VHL	Y112H (c.334T>C)	1865:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183867	10183867	C	A	VHL	Y112* (c.336C>A)	1766:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183868	10183868	C	-	VHL	R113FS (c.337delC)	2143:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183868	10183868	C	T	VHL	R113* (c.337C>T)	1796:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183871	10183871	G	A	VHL	G114S (c.340G>A)	2026:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183871	10183871	G	C	VHL	G114R (c.340G>C)	1857:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1857:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183871	10183871	G	T	VHL	G114C (c.340G>T)	1797:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1797:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10183872	10183872	G	A	VHL	Splicing alteration (c.340+1G>A)	2114:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|2114:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188196	10188196	A	C	VHL	Splicing alteration (c.341-2A>C)	2133:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|2133:4:C:Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188200	10188200	C	T	VHL	H115Y (c.343C>T)	1921:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188201	10188201	A	-	VHL	H115FS (c.344delA)	2057:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188201	10188201	A	C	VHL	H115P (c.344A>C)	1885:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188201	10188201	A	G	VHL	H115R (c.344A>G)	2000:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188202	10188202	C	A	VHL	H115Q (c.345C>A)	1742:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188202	10188202	C	G	VHL	H115Q (c.345C>G)	1957:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1957:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188203	10188203	C	G	VHL	L116V (c.346C>G)	1820:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188206	10188206	-	T	VHL	W117fs (c.349dupT)	2027:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188208	10188208	G	T	VHL	W117C (c.351G>T)	1767:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1767:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188210	10188210	T	C	VHL	L118P (c.353T>C)	1798:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1798:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1798:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188214	10188214	C	G	VHL	F119L (c.357C>G)	1743:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1743:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation|1743:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188215	10188215	A	G	VHL	R120G (c.358A>G)	1914:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188219	10188219	A	G	VHL	D121G (c.362A>G)	1813:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188221	10188222	GC	AT	VHL	A122I (c.364_365GC>AT)	2028:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|2028:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188224	10188224	G	-	VHL	G123FS (c.367delG)	1905:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188232	10188232	-	C	VHL	D126FS (c.375_376insC)	1918:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Pathogenic:Germline Mutation
3	10188240	10188240	T	G	VHL	L128R (c.383T>G)	1886:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188241	10188241	T	-	VHL	L129fs (c.384delT)	1996:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188243	10188243	T	C	VHL	L129P (c.386T>C)	2034:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188245	10188245	G	C	VHL	V130L (c.388G>C)	1970:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188247	10188248	TA	-	VHL	N131P (c.390_391delTA)	1800:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188250	10188250	C	A	VHL	N131K (c.393C>A)	1953:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1953:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188251	10188251	C	T	VHL	Q132* (c.394C>T)	1994:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188252	10188252	A	C	VHL	Q132P (c.395A>C)	2125:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188261	10188261	T	-	VHL	L135FS (c.404delT)	1906:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188261	10188261	T	A	VHL	L135* (c.404T>A)	1769:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188264	10188264	T	C	VHL	F136S (c.407T>C)	1801:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1801:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1801:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1801:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188264	10188264	T	G	VHL	F136C (c.407T>G)	1814:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1814:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188269	10188269	C	A	VHL	P138T (c.412C>A)	1928:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188287	10188287	G	T	VHL	G144* (c.430G>T)	1850:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188290	10188290	C	T	VHL	Q145* (c.433C>T)	1883:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188293	10188293	C	-	VHL	P146fs (c.436delC)	2055:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188302	10188302	G	-	VHL	A149fs (c.445delG)	2042:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188302	10188302	G	A	VHL	A149T (c.445G>A)	1744:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188302	10188302	G	T	VHL	A149S (c.445G>T)	820:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|820:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188302	10188315	GCCAATATCACACT	-	VHL	N150fs (c.445_458del)	2029:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188306	10188306	A	G	VHL	N150S (c.449A>G)	2162:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188309	10188309	T	C	VHL	I151T (c.452T>C)	1871:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1871:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188310	10188310	C	G	VHL	I151M (c.453C>G)	2030:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188315	10188315	T	C	VHL	L153P (c.458T>C)	1923:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1923:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188318	10188318	C	T	VHL	P154L (c.461C>T)	1782:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1782:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1782:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188319	10188319	A	-	VHL	P154fs (c.462delA)	1771:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188319	10188319	A	C	VHL	P154P (c.462A>C)	1962:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1962:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188321	10188321	G	C	VHL	Splicing alteration (c.463+1G>C)	1998:2:C:Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188322	10188322	C	T	VHL	Splicing alteration (c.463+2C>T)	1993:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10188328	10188328	C	T	VHL	Splicing alteration (c.463+8C>T)	2292:2:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191469	10191469	A	G	VHL	Splicing alteration (c.464-2A>G)	2078:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|2078:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191469	10191469	A	T	VHL	Splicing alteration (c.464-2A>T)	1992:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191470	10191470	G	A	VHL	Splicing alteration (c.464-1G>A)	1974:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191470	10191470	G	C	VHL	Splicing alteration (c.464-1G>C)	2077:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191470	10191470	G	T	VHL	Splicing alteration (c.464-1G>T)	1990:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1990:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191471	10191471	T	A	VHL	V155E (c.464T>A)	1909:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191471	10191471	T	G	VHL	V155G (c.464T>G)	1934:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191473	10191473	T	A	VHL	Y156N (c.466T>A)	2013:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191473	10191473	T	G	VHL	Y156D (c.466T>G)	1967:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191474	10191474	A	G	VHL	Y156C (c.467A>G)	1946:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1946:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation|1946:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191475	10191475	T	G	VHL	Y156* (c.468T>G)	1968:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191477	10191477	C	T	VHL	T157I (c.470C>T)	1745:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1745:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1745:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191479	10191479	C	G	VHL	L158V (c.472C>G)	1803:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1803:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1803:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191480	10191480	T	C	VHL	L158P (c.473T>C)	1738:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191481	10191483	GAA	C	VHL	L158fs (c.474_476delGAAinsC)	2137:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191482	10191482	A	-	VHL	K159fs (c.475delA)	2098:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191484	10191484	-	CA	VHL	K159fs (c.477_478insCA)	2040:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191485	10191486	GA	-	VHL	E160FS (c.478_479delGA)	2032:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191486	10191487	AG	-	VHL	E160FS (c.479_480delAG)	1919:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191488	10191488	C	G	VHL	R161G (c.481C>G)	1915:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1915:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191488	10191488	C	T	VHL	R161* (c.481C>T)	1804:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1804:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Pathogenic:Germline Mutation|1804:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1804:3:C:Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191489	10191489	G	A	VHL	R161Q (c.482G>A)	1746:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1746:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1746:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation|1746:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191489	10191489	G	C	VHL	R161P (c.482G>C)	1855:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191490	10191490	A	-	VHL	C162FS (c.483delA)	2035:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191491	10191491	T	C	VHL	C162R (c.484T>C)	1772:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191492	10191492	G	A	VHL	C162Y (c.485G>A)	1824:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1824:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191492	10191492	G	T	VHL	C162F (c.485G>T)	1773:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1773:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1773:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191493	10191493	C	G	VHL	C162W (c.486C>G)	1774:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1774:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1774:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191495	10191495	T	A	VHL	L163H (c.488T>A)	2033:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191497	10191497	C	T	VHL	Q164* (c.490C>T)	1845:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1845:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191498	10191498	A	G	VHL	Q164R (c.491A>G)	1856:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191498	10191498	A	T	VHL	Q164L (c.491A>T)	2079:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191503	10191503	G	T	VHL	V166F (c.496G>T)	1825:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191504	10191504	T	A	VHL	V166D (c.497T>A)	1775:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191506	10191506	C	T	VHL	R167W (c.499C>T)	1747:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1747:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1747:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191507	10191507	G	A	VHL	R167Q (c.500G>A)	1739:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1739:3:C:Von Hippel-Lindau Disease::Diagnostic:Supports:Positive:Germline Mutation|1739:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation|1739:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1739:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191507	10191507	G	T	VHL	R167L (c.500G>T)	1916:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1916:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191513	10191513	T	C	VHL	L169P (c.506T>C)	1887:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1887:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1887:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191515	10191515	G	T	VHL	V170F (c.508G>T)	1806:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191516	10191516	T	A	VHL	V170D (c.509T>A)	1826:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1826:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191516	10191516	T	G	VHL	V170G (c.509T>G)	1935:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1935:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1935:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191530	10191530	T	G	VHL	Y175D (c.523T>G)	1846:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191532	10191532	C	-	VHL	Y175FS (c.525delC)	2138:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191532	10191532	C	G	VHL	Y175* (c.525C>G)	1969:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191533	10191533	A	-	VHL	Y175fs (c.526delA)	1780:4:C:Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191535	10191535	G	-	VHL	R176fs (c.528delG)	1907:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1907:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191536	10191536	A	T	VHL	R177* (c.529A>T)	1827:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191540	10191540	T	A	VHL	L178Q (c.533T>A)	1997:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191540	10191540	T	C	VHL	L178P (c.533T>C)	1748:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1748:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1748:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191540	10191540	T	G	VHL	L178R (c.533T>G)	1888:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1888:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191545	10191545	A	G	VHL	I180V (c.538A>G)	1807:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191555	10191555	C	A	VHL	S183* (c.548C>A)	1784:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1784:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1784:3:C:Renal Cell Carcinoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191558	10191558	T	C	VHL	L184P (c.551T>C)	1776:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1776:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191558	10191558	T	G	VHL	L184R (c.551T>G)	1808:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1808:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191562	10191562	C	G	VHL	Y185* (c.555C>G)	1809:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191563	10191563	G	A	VHL	E186K (c.556G>A)	1778:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191563	10191563	G	T	VHL	E186* (c.556G>T)	1777:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191569	10191569	C	-	VHL	L188fs (c.562delC)	2139:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191569	10191569	C	G	VHL	L188V (c.562C>G)	1836:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191570	10191570	T	A	VHL	L188Q (c.563T>A)	1861:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191570	10191570	T	C	VHL	L188P (c.563T>C)	1852:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191570	10191570	T	G	VHL	L188R (c.563T>G)	1924:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1924:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191578	10191578	C	-	VHL	H191FS (c.571delC)	1958:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191588	10191589	TG	-	VHL	V194FS (c.581_582delTG)	2022:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191590	10191590	C	T	VHL	Q195* (c.583C>T)	1810:1:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1810:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1810:3:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|1810:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191591	10191592	AG	-	VHL	Q195fs (c.584_585delAG)	2140:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191593	10191593	A	T	VHL	K196* (c.586A>T)	1913:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191596	10191596	G	-	VHL	D197FS (c.589delG)	2141:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191600	10191600	T	A	VHL	L198Q  (c.593T>A)	2010:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation|2010:3:C:Adrenal Gland Pheochromocytoma::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191605	10191605	C	T	VHL	R200W (c.598C>T)	631:4:C:Chuvash Polycythemia:Ruxolitinib:Predictive:Supports:Sensitivity/Response:Germline Mutation
3	10191647	10191647	T	G	VHL	*214G (c.640T>G)	2488:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191648	10191648	G	T	VHL	*214L (c.641G>T)	1986:4:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191649	10191649	A	G	VHL	*214W (c.642A>G)	1987:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191649	10191649	A	T	VHL	*214C (c.642A>T)	1988:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191656	10191656	C	G	VHL	3'UTR alteration (c.639+10C>G)	2024:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	10191719	10191719	C	A	VHL	3'UTR alteration (c.642+70C>A)	2152:2:C:Von Hippel-Lindau Disease::Predisposing:Supports:Uncertain Significance:Germline Mutation
3	37035039	37035039	A	T	MLH1	M1L	747:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37035075	37035075	G	-	MLH1	E13FS*3	725:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37038139	37038139	T	C	MLH1	V49A	745:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37038187	37038187	G	A	MLH1	G65D	759:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37038192	37038192	G	A	MLH1	G67R	757:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37038196	37038196	T	G	MLH1	I68S	758:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37042536	37042536	C	T	MLH1	R100*	741:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37045935	37045935	C	T	MLH1	T117M	743:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37048546	37048546	C	T	MLH1	Q149*	753:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37053551	37053551	T	-	MLH1	V213FS	750:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37053589	37053589	C	T	MLH1	R226*	754:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37056036	37056036	G	A	MLH1	C.790+1G>A	731:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37058999	37058999	C	G	MLH1	R265G	749:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37067359	37067359	G	A	MLH1	A424T	752:1:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37067365	37067365	C	-	MLH1	Q426FS	744:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37070334	37070334	T	C	MLH1	M490T	769:1:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37081718	37081719	GT	AG	MLH1	V534R	728:1:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37081726	37081726	T	-	MLH1	P536FS	756:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37081770	37081770	A	C	MLH1	N551T	751:1:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37089094	37089095	GG	-	MLH1	G606FS*2	730:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37089130	37089132	AAG	-	MLH1	K618DEL	733:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37090406	37090406	C	-	MLH1	D667FS	746:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37090447	37090447	C	T	MLH1	A681V	760:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37090464	37090464	C	-	MLH1	R687FS	735:2:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	37092143	37092143	A	T	MLH1	*757L	748:1:E:Lynch Syndrome::Predisposing:Supports:Uncertain Significance:Somatic Mutation
3	38182641	38182641	T	C	MYD88	L265P	424:1:D:Waldenstrm's Macroglobulinemia:IMG-2005-5,IRAK-1/4 Inhibitor:Predictive:Supports:Sensitivity/Response:Somatic Mutation|424:2:B:Chronic Lymphocytic Leukemia::Prognostic:Supports:Better Outcome:Somatic Mutation|424:4:B:Waldenstrm's Macroglobulinemia:Ibrutinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
3	41266124	41266124	A	G	CTNNB1	T41A	1285:3:B:Desmoid Fibromatosis::Prognostic:Supports:Better Outcome:Somatic Mutation|1285:4:B:Desmoid Fibromatosis::Diagnostic:Supports:Positive:Somatic Mutation
3	41266136	41266136	T	C	CTNNB1	S45P	1287:1:B:Desmoid Fibromatosis::Prognostic:Supports:Better Outcome:Somatic Mutation|1287:3:B:Desmoid Fibromatosis::Diagnostic:Supports:Positive:Somatic Mutation
3	41266137	41266137	C	T	CTNNB1	S45F	1286:2:C:Desmoid Fibromatosis:Meloxicam:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|1286:3:B:Desmoid Fibromatosis::Prognostic:Supports:Poor Outcome:Somatic Mutation|1286:4:B:Desmoid Fibromatosis::Diagnostic:Supports:Positive:|1286:4:B:Desmoid Fibromatosis::Diagnostic:Supports:Positive:Somatic Mutation
3	105439026	105439026	G	A	CBLB	RS2305035	643:2:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Better Outcome:Germline Polymorphism
3	138665163	138665163	G	C	FOXL2	C134W	198:4:B:Ovarian Granulosa Cell Tumor::Diagnostic:Supports:Positive:Somatic Mutation|198:5:A:Ovarian Sex Cord-stromal Tumours::Diagnostic:Supports:Positive:Somatic Mutation
3	178921567	178921567	A	G	PIK3CA	D350G	1653:2:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation
3	178928226	178928226	C	T	PIK3CA	P471L	294:3:C:Merkel Cell Carcinoma:Idelalisib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
3	178936082	178936082	G	A	PIK3CA	E542K	103:2:E:Colorectal Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|103:2:C:Head And Neck Squamous Cell Carcinoma:Apitolisib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|103:3:B:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|103:3:D:Breast Cancer:Rapamycin (Sirolimus):Predictive:Supports:Sensitivity/Response:Somatic Mutation|103:3:D:Thyroid Cancer:Perifosine,Temsirolimus:Predictive:Supports:Sensitivity/Response:Somatic Mutation|103:3:B:Colorectal Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|103:4:D:Breast Cancer:CH5132799:Predictive:Supports:Sensitivity/Response:Somatic Mutation|103:4:B:Colorectal Cancer:Regorafenib:Predictive:Does Not Support:N/A:Somatic Mutation
3	178936091	178936091	G	A	PIK3CA	E545K	104:0:B:Breast Cancer:Ado-trastuzumab Emtansine:Predictive:Supports:Sensitivity/Response:Somatic Mutation|104:0:D:Breast Cancer:Pictilisib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|104:1:C:Cancer:Apitolisib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|104:2:D:Her2-receptor Positive Breast Cancer:Trastuzumab:Predictive:Supports:Resistance:Somatic Mutation|104:2:D:Lung Adenocarcinoma:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|104:2:D:Non-small Cell Lung Carcinoma:PI103:Predictive:Supports:Sensitivity/Response:Somatic Mutation|104:2:B:Lung Adenocarcinoma:Gefitinib,Erlotinib,Afatinib:Predictive:Supports:Resistance:Somatic Mutation|104:2:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|104:2:C:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Does Not Support:Resistance:Somatic Mutation|104:3:C:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|104:3:D:Breast Cancer:MK-2206,Pictilisib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
3	178936092	178936092	A	G	PIK3CA	E545G	883:2:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation
3	178952085	178952085	A	G	PIK3CA	H1047R	107:0:B:Breast Cancer:Trastuzumab:Predictive:Supports:Resistance:Somatic Mutation|107:0:B:Breast Cancer:Ado-trastuzumab Emtansine:Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:0:B:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|107:1:D:Head And Neck Cancer:BEZ235 (NVP-BEZ235, Dactolisib):Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:1:D:Head And Neck Cancer:BYL719 (Alpelisib):Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:2:B:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Does Not Support:Resistance:Somatic Mutation|107:2:C:Colorectal Cancer:Panitumumab,Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|107:2:D:Head And Neck Cancer:Cetuximab,BEZ235 (NVP-BEZ235, Dactolisib):Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:2:D:Non-small Cell Lung Carcinoma:PI103:Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:2:D:Head And Neck Cancer:BEZ235 (NVP-BEZ235, Dactolisib):Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:2:D:Head And Neck Squamous Cell Carcinoma:Taselisib (GDC-0032):Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:2:C:Her2-receptor Positive Breast Cancer:Everolimus,Fulvestrant:Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:3:D:Breast Cancer:Trastuzumab:Predictive:Supports:Resistance:Somatic Mutation|107:3:D:Thyroid Cancer:Perifosine,Temsirolimus:Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:3:D:Her2-receptor Positive Breast Cancer:AZD5363,Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:3:D:Her2-receptor Positive Breast Cancer:AZD5363,Trastuzumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:3:D:Lung Adenocarcinoma:BEZ235 (NVP-BEZ235, Dactolisib):Predictive:Supports:Sensitivity/Response:Somatic Mutation|107:4:D:Breast Cancer:CH5132799:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	1803568	1803568	C	G	FGFR3	S249C	628:2:C:Urothelial Carcinoma:Pazopanib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	1806099	1806099	A	G	FGFR3	Y375C	196:3:B:Bladder Carcinoma::Diagnostic:Supports:Positive:Somatic Mutation
4	55141036	55141036	T	A	PDGFRA	V561D	941:1:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|941:2:D:Cancer:Imatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
4	55141036	55141036	T	C	PDGFRA	V561A	247:3:D:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55141083	55141083	C	T	PDGFRA	P577S	862:3:D:Melanoma:Imatinib,Crenolanib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55144547	55144547	C	T	PDGFRA	FIP1L1-PDGFRA T674I	577:2:C:Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|577:3:C:Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|577:3:D:Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1:Ponatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55152090	55152090	G	A	PDGFRA	R841K	863:3:D:Melanoma:Imatinib,Crenolanib:Predictive:Supports:Sensitivity/Response:
4	55152092	55152092	G	T	PDGFRA	D842Y	100:4:D:Gastrointestinal Stromal Tumor:Crenolanib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55152092	55152093	GA	AT	PDGFRA	D842I	98:4:D:Gastrointestinal Stromal Tumor:Crenolanib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55152093	55152093	A	T	PDGFRA	D842V	99:2:D:Cancer:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|99:2:D:Gastrointestinal Stromal Tumor:Sunitinib:Predictive:Supports:Resistance:Somatic Mutation|99:3:B:Gastrointestinal Stromal Tumor::Diagnostic:Supports:Negative:Somatic Mutation|99:3:D:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|99:4:D:Gastrointestinal Stromal Tumor:Crenolanib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|99:4:B:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55152093	55152097	ACATC	TCATG	PDGFRA	DI842-843VM	102:4:D:Gastrointestinal Stromal Tumor:Crenolanib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55152095	55152097	ATC	-	PDGFRA	I843DEL	101:2:D:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|101:3:D:Gastrointestinal Stromal Tumor:Crenolanib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55152101	55152101	C	T	PDGFRA	H845Y	864:3:D:Melanoma:Crenolanib,Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55152126	55152126	G	A	PDGFRA	G853D	865:3:D:Melanoma:Crenolanib,Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55592185	55592185	-	GCCTAT	KIT	Y503_F504insAY	946:2:D:Cancer:Imatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
4	55593464	55593464	A	C	KIT	M541L	201:2:C:Chronic Leukemia:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|201:4:B:Chronic Myeloid Leukemia::Diagnostic:Does Not Support:Negative:Somatic Mutation
4	55593603	55593608	TGGAAG	-	KIT	W557_K558DELWK	961:2:D:Cancer:Imatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
4	55593610	55593610	T	A	KIT	V559D	968:2:D:Cancer:MLN518,SU11248,Imatinib,BMS-354825,PD-180970:Predictive:Supports:Sensitivity/Response:Somatic Mutation|968:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55593612	55593614	GTT	-	KIT	V560DEL	202:5:C:Thymic Carcinoma:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55593613	55593613	T	G	KIT	V560G	972:2:D:Cancer:Imatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
4	55593661	55593661	T	C	KIT	L576P	72:3:D:Non-small Cell Lung Carcinoma:Dasatinib,Imatinib,Nilotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|72:3:D:Melanoma:Imatinib,Nilotinib,Sorafenib:Predictive:Supports:Resistance:Somatic Mutation|72:3:D:Melanoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55593669	55593671	GAT	-	KIT	D579DEL	977:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55594221	55594221	A	G	KIT	K642E	978:2:C:Melanoma::Prognostic:Supports:Better Outcome:Somatic Mutation|978:2:D:Cancer:Imatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
4	55594258	55594258	T	C	KIT	V654A	73:3:D:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|73:3:B:Gastrointestinal Stromal Tumor:Sunitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55595519	55595519	C	T	KIT	T670I	1267:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55599299	55599299	T	G	KIT	C809G	1264:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55599320	55599320	G	C	KIT	D816H	983:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55599321	55599321	A	T	KIT	D816V	65:2:D:Cancer:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|65:4:B:Acute Myeloid Leukemia::Prognostic:Supports:Poor Outcome:Somatic Mutation|65:4:B:Systemic Mastocytosis:Midostaurin:Predictive:Supports:Sensitivity/Response:Somatic Mutation|65:4:B:Systemic Mastocytosis::Prognostic:Supports:Poor Outcome:Somatic Mutation
4	55599332	55599332	G	T	KIT	D820Y	986:2:C:Melanoma::Prognostic:Supports:N/A:Somatic Mutation|986:3:C:Melanoma:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55599333	55599333	A	C	KIT	D820A	1265:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55599333	55599333	A	G	KIT	D820G	1266:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55599340	55599340	T	A	KIT	N822K	1263:2:D:Cancer:Imatinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|1263:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55599341	55599341	T	G	KIT	Y823D	989:3:C:Gastrointestinal Stromal Tumor:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
4	55602765	55602765	G	C	KIT	RS3733542	482:1:B:Acute Myeloid Leukemia:Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Germline Polymorphism
4	55955969	55955969	C	T	KDR	A1065T	467:3:D:Angiosarcoma:Sorafenib,Sunitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55961059	55961059	G	A	KDR	R961W	502:1:C:Colorectal Adenocarcinoma:Regorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	55968180	55968180	T	A	KDR	D717V	468:3:D:Angiosarcoma:Sunitinib,Sorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
4	89052323	89052323	G	T	ABCG2	Q141K	260:3:B:Ovarian Cancer::Prognostic:Supports:Better Outcome:Germline Polymorphism
5	1286516	1286516	C	A	TERT	RS2736100	421:2:B:Brain Glioma::Predisposing:Supports:Positive:Germline Polymorphism
5	1295228	1295228	G	A	TERT	C228T	248:3:B:Thyroid Cancer::Diagnostic:Supports:Positive:Somatic Mutation|248:5:B:Papillary Thyroid Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation
5	170837547	170837547	-	TCTG	NPM1	W288FS	87:3:E:Acute Myeloid Leukemia:Induction Therapy:Predictive:Supports:Sensitivity/Response:Somatic Mutation|87:3:D:Acute Myeloid Leukemia:NSC348884:Predictive:Supports:Sensitivity/Response:Somatic Mutation|87:4:B:Acute Myeloid Leukemia::Diagnostic:Supports:Positive:Somatic Mutation|87:4:B:Acute Myeloid Leukemia::Diagnostic:Does Not Support:Positive:Somatic Mutation
5	176942767	176942767	G	A	DDX41	R164W	814:3:C:Hematologic Cancer::Predisposing:Supports:Positive:Germline Mutation
6	117630062	117630062	A	G	ROS1	CD74-ROS1 L2155S	517:3:D:Non-small Cell Lung Carcinoma:Crizotinib,Foretinib,TAE684:Predictive:Supports:Resistance:Somatic Mutation
6	117631376	117631376	C	G	ROS1	CD74-ROS1 G2101A	518:2:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|518:2:D:Non-small Cell Lung Carcinoma:Foretinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
6	117638347	117638347	C	T	ROS1	CD74-ROS1 G2032R	465:2:D:Non-small Cell Lung Carcinoma:Foretinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|465:3:D:Non-small Cell Lung Carcinoma:Lorlatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|465:3:D:Non-small Cell Lung Carcinoma:Cabozantinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|465:3:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|465:3:D:Non-small Cell Lung Carcinoma:Crizotinib,Brigatinib,Ceritinib,AZD3463:Predictive:Supports:Resistance:Somatic Mutation|465:3:D:Non-small Cell Lung Carcinoma:Cabozantinib,Foretinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|465:4:C:Lung Adenocarcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
6	117638347	117638347	C	T	ROS1	G2032R	1271:1:C:Lung Adenocarcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
6	117638365	117638365	G	T	ROS1	CD74-ROS1 L2026M	516:2:D:Non-small Cell Lung Carcinoma:Foretinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|516:2:D:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|516:3:D:Non-small Cell Lung Carcinoma:Lorlatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
6	152415537	152415537	T	C	ESR1	S463P	692:2:D:Estrogen-receptor Positive Breast Cancer:Aromatase Inhibitor:Predictive:Supports:Resistance:Somatic Mutation
6	152419920	152419921	TC	AG	ESR1	L536Q	46:3:D:Breast Cancer:Hormone Therapy:Predictive:Supports:Resistance:Somatic Mutation|46:5:D:Breast Cancer:Tamoxifen,Fulvestrant:Predictive:Supports:Sensitivity/Response:Somatic Mutation
6	152419922	152419922	T	A	ESR1	Y537N	49:3:D:Breast Cancer:Hormone Therapy:Predictive:Supports:Resistance:Somatic Mutation|49:5:D:Breast Cancer:Tamoxifen,Fulvestrant:Predictive:Supports:Sensitivity/Response:Somatic Mutation
6	152419923	152419923	A	C	ESR1	Y537S	50:3:D:Breast Cancer:Hormone Therapy:Predictive:Supports:Resistance:Somatic Mutation|50:5:D:Breast Cancer:Tamoxifen,Fulvestrant:Predictive:Supports:Sensitivity/Response:Somatic Mutation
6	152419923	152419923	A	G	ESR1	Y537C	48:3:D:Breast Cancer:Hormone Therapy:Predictive:Supports:Resistance:Somatic Mutation|48:5:D:Breast Cancer:Tamoxifen,Fulvestrant:Predictive:Supports:Sensitivity/Response:Somatic Mutation
6	152419926	152419926	A	G	ESR1	D538G	47:2:B:Breast Cancer:Letrozole,Palbociclib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|47:3:D:Breast Cancer:Hormone Therapy:Predictive:Supports:Resistance:Somatic Mutation|47:5:D:Breast Cancer:Tamoxifen,Fulvestrant:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	6426892	6426892	C	T	RAC1	P29S	367:4:D:Melanoma:Dabrafenib,Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation
7	55221822	55221822	C	T	EGFR	A289V	996:3:D:Malignant Glioma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55227884	55227884	C	T	EGFR	R451C	454:2:D:Colorectal Cancer:Cetuximab,Panitumumab,Sym004:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55227926	55227926	G	A	EGFR	G465R	443:4:C:Colorectal Cancer:Sym004:Predictive:Supports:Sensitivity/Response:Somatic Mutation|443:4:C:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Supports:Resistance:Somatic Mutation
7	55227933	55227933	A	C	EGFR	K467T	455:3:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|455:3:D:Colorectal Cancer:Panitumumab,Sym004:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55228009	55228009	C	A	EGFR	S492R	453:2:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|453:4:C:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|453:4:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|453:4:D:Colorectal Cancer:Sym004,Panitumumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55241707	55241707	G	A	EGFR	G719S	134:0:D:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|134:3:B:Non-small Cell Lung Carcinoma:Erlotinib,Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|134:4:D:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|134:4:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55241708	55241708	G	C	EGFR	G719A	999:0:C:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|999:2:C:Non-small Cell Lung Carcinoma:Erlotinib,Gefitinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	55241722	55241722	G	A	EGFR	G724S	317:4:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55242467	55242467	A	G	EGFR	E746G	724:1:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55242487	55242487	C	T	EGFR	P753S	460:3:C:Skin Squamous Cell Carcinoma:Rapamycin (Sirolimus),Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55242500	55242500	A	G	EGFR	K757R	723:3:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55242511	55242511	G	T	EGFR	D761Y	712:3:C:Non-small Cell Lung Carcinoma:Erlotinib,Gefitinib:Predictive:Supports:Resistance:Somatic Mutation
7	55248992	55248992	-	TCCAGGAAGCCT	EGFR	A763_Y764insFQEA	1515:0:D:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55249000	55249000	-	GCCAGCGTG	EGFR	A767_V769dupASV	1579:0:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation
7	55249005	55249005	G	T	EGFR	S768I	562:0:D:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation|562:0:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation|562:2:C:Lung Adenocarcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|562:2:C:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|562:3:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55249009	55249009	-	GCCAGCGTG	EGFR	V769_770insASV	736:3:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55249012	55249012	-	AACCCCCAC	EGFR	H773_V774insNPH	1513:0:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation
7	55249012	55249012	-	GGCACA	EGFR	D770_N771insGT	1566:0:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation
7	55249012	55249012	-	GGGTTA	EGFR	D770_N771insGL	1514:0:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation
7	55249013	55249013	-	GCGTGGACA	EGFR	D770_N771insSVD	1445:0:D:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation
7	55249071	55249071	C	T	EGFR	T790M	34:0:C:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|34:1:E:Non-small Cell Lung Carcinoma:Staurosporine:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:1:C:Lung Adenocarcinoma:Osimertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:2:D:Non-small Cell Lung Carcinoma:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:2:C:Lung Adenocarcinoma:Osimertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:2:D:Non-small Cell Lung Carcinoma:Canertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:2:D:Non-small Cell Lung Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:2:D:Non-small Cell Lung Carcinoma:Osimertinib,Rociletinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:3:B:Lung Adenocarcinoma:Gefitinib,Erlotinib:Predictive:Supports:Resistance:Somatic Mutation|34:3:D:Non-small Cell Lung Carcinoma:Osimertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:3:C:Non-small Cell Lung Carcinoma:Pemetrexed,Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:3:B:Non-small Cell Lung Carcinoma:Afatinib,Gefitinib,Erlotinib:Predictive:Supports:Resistance:Somatic Mutation|34:3:D:Non-small Cell Lung Carcinoma:PF 00299804:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:3:D:Cancer:Erlotinib:Predictive:Supports::Somatic Mutation|34:3:B:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|34:3:D:Non-small Cell Lung Carcinoma:Rociletinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:3:B:Non-small Cell Lung Carcinoma:Osimertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:4:D:Non-small Cell Lung Carcinoma:Lapatinib:Predictive:Supports:Resistance:Somatic Mutation|34:4:B:Non-small Cell Lung Carcinoma:Rociletinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:4:B:Non-small Cell Lung Carcinoma:Afatinib:Predictive:Supports:Resistance:Somatic Mutation|34:4:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|34:4:B:Non-small Cell Lung Carcinoma:Osimertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:4:B:Non-small Cell Lung Carcinoma:Dacomitinib:Predictive:Supports:Resistance:Somatic Mutation|34:5:A:Non-small Cell Lung Carcinoma:Osimertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|34:5:D:Lung Cancer:Gefitinib,AEE788:Predictive:Supports:Resistance:Somatic Mutation|34:5:A:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Resistance:Somatic Mutation
7	55249091	55249091	T	A	EGFR	C797S	415:1:C:Lung Adenocarcinoma:Osimertinib:Predictive:Supports:Resistance:Somatic Mutation|415:3:B:Non-small Cell Lung Carcinoma:Osimertinib:Predictive:Supports:Resistance:Somatic Mutation
7	55249092	55249092	G	A	EGFR	C797Y	1574:0:D:Malignant Mesothelioma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55249118	55249118	A	G	EGFR	K806E	1895:2:C:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	55259434	55259434	G	A	EGFR	R831H	1017:0:D:Malignant Mesothelioma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55259515	55259515	T	G	EGFR	L858R	33:0:D:Lung Adenocarcinoma:Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:C:Lung Adenocarcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Hematologic Cancer:Cetuximab:Predictive:::Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:MEDI4736:Predictive:::Somatic Mutation|33:0:D:Lung Small Cell Carcinoma:Erlotinib:Predictive:::Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Malignant Glioma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:PF 00299804:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:0:D:Non-small Cell Lung Carcinoma:Canertinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:1:C:Lung Adenocarcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:2:B:Lung Adenocarcinoma:Gefitinib:Predictive:Does Not Support:Reduced Sensitivity:Somatic Mutation|33:2:D:Non-small Cell Lung Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:2:C:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:D:Cancer:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:D:Cancer:Gefitinib,Erlotinib,AEE788:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Lung Adenocarcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma:Gefitinib,Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Better Outcome:Somatic Mutation|33:3:B:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:B:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:D:Non-small Cell Lung Carcinoma:Gefitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:B:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:4:B:Non-small Cell Lung Carcinoma:Gefitinib,Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:5:B:Non-small Cell Lung Carcinoma:Dacomitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:5:A:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|33:5:A:Non-small Cell Lung Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	55259532	55259532	G	A	EGFR	A864T	1187:0:D:Non-small Cell Lung Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	87138645	87138645	A	G	ABCB1	I1145I	263:2:B:Non-small Cell Lung Carcinoma:Cisplatin,Carboplatin:Predictive:Supports:Sensitivity/Response:Germline Mutation|263:3:B:Breast Cancer::Prognostic:Supports:Better Outcome:Germline Polymorphism
7	87160618	87160618	A	C	ABCB1	S893A/T	451:3:B:Breast Cancer::Prognostic:Supports:Better Outcome:Germline Polymorphism
7	87160618	87160618	A	T	ABCB1	S893T	262:3:B:Ovarian Cancer:Paclitaxel:Predictive:Supports:Sensitivity/Response:Germline Mutation
7	116423407	116423407	G	A	MET	D1228N	649:2:C:Non-small Cell Lung Carcinoma:Crizotinib:Predictive:Supports:Resistance:Somatic Mutation
7	116423408	116423408	A	T	MET	D1228V	798:4:C:Non-small Cell Lung Carcinoma:Savolitinib:Predictive:Supports:Resistance:Somatic Mutation|798:4:C:Non-small Cell Lung Carcinoma:Cabozantinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	128846398	128846398	C	T	SMO	L412F	1570:0:D:Basal Cell Carcinoma:Vismodegib:Predictive:Supports:Resistance:Somatic Mutation|1570:0:C:Basal Cell Carcinoma:Vismodegib:Predictive:Supports:Resistance:Somatic Mutation
7	128849189	128849189	G	C	SMO	D473H	299:3:D:Brain Medulloblastoma:Saridegib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|299:3:D:Basal Cell Carcinoma:Vismodegib:Predictive:Supports:Resistance:Somatic Mutation|299:3:C:Brain Medulloblastoma:Vismodegib:Predictive:Supports:Resistance:Somatic Mutation
7	140434507	140434507	G	T	BRAF	P731T	2224:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	140453118	140453118	C	T	BRAF	G606E	2223:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	140453134	140453134	T	C	BRAF	K601E	584:3:D:Skin Melanoma:Trametinib,Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453135	140453136	CA	AT	BRAF	V600D	11:0:D:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|11:5:B:Melanoma:Dabrafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453136	140453136	A	T	BRAF	V600E	12:0:B:Melanoma:Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:0:B:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:0:C:Ganglioglioma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:0:B:Colorectal Cancer:Bevacizumab:Predictive:Supports:Resistance:Somatic Mutation|12:0:C:Ovarian Cystadenocarcinoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:0:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|12:2:D:Colorectal Cancer:Capecitabine,Vemurafenib,Bevacizumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:C:Colorectal Cancer:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:B:Hairy Cell Leukemia:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:D:Melanoma:Selumetinib (AZD6244),BEZ235 (NVP-BEZ235, Dactolisib):Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:C:Non-small Cell Lung Carcinoma:Dabrafenib:Predictive:Supports:Resistance:Somatic Mutation|12:2:C:Multiple Myeloma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:D:Colorectal Cancer:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:C:Melanoma:Pictilisib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:D:Colorectal Cancer:PLX4720,Nutlin-3:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:2:B:Melanoma:Dacarbazine,Temozolomide:Predictive:Does Not Support:N/A:Somatic Mutation|12:2:C:Colorectal Cancer:Vemurafenib,Panitumumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:D:Colorectal Cancer:Vemurafenib,Gefitinib,Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:B:Colorectal Adenocarcinoma:Panitumumab,Trametinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|12:3:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|12:3:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|12:3:D:Cancer:Cobimetinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:C:Laryngeal Squamous Cell Carcinoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:C:Anaplastic Thyroid Carcinoma:Vemurafenib,Pertuzumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:B:Ovarian Cancer:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:C:Gastrointestinal Neuroendocrine Tumor:Dabrafenib,Trametinib,Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:D:Melanoma:Trametinib,PD0325901:Predictive:Does Not Support:Resistance:Somatic Mutation|12:3:B:Skin Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:B:Thyroid Cancer::Diagnostic:Supports:Positive:Somatic Mutation|12:3:B:Papillary Thyroid Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|12:3:B:Melanoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|12:3:B:Colorectal Cancer:Oxaliplatin:Predictive:Supports:Resistance:Somatic Mutation|12:3:B:Colorectal Cancer:Vemurafenib,Panitumumab:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|12:3:B:Anaplastic Thyroid Carcinoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:C:Cholangiocarcinoma:Vemurafenib,Irinotecan,Panitumumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:B:Colorectal Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|12:3:B:Myeloma::Prognostic:Supports:Poor Outcome:Somatic Mutation|12:3:B:Colorectal Cancer:Dabrafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|12:3:C:Multiple Myeloma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:D:Colorectal Cancer:Sorafenib,Panitumumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:B:Colorectal Cancer:Irinotecan:Predictive:Supports:Resistance:Somatic Mutation|12:3:C:Cholangiocarcinoma:Trametinib DMSO,Dabrafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:B:Papillary Thyroid Carcinoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:D:Colorectal Cancer:BEZ235 (NVP-BEZ235, Dactolisib),GDC-0879:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:D:Colorectal Cancer:PLX4720,GDC0941:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:C:Cholangiocarcinoma:Dabrafenib,Trametinib DMSO:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:3:B:Colorectal Cancer:Panitumumab,Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|12:4:B:Melanoma:Dabrafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Colorectal Cancer:Cetuximab,Irinotecan,Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Skin Melanoma:Trametinib,Dabrafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:A:Non-small Cell Lung Carcinoma:Dabrafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Colorectal Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|12:4:B:Colorectal Cancer:Dabrafenib,Panitumumab,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Does Not Support:Resistance:Somatic Mutation|12:4:B:Melanoma:Vemurafenib,Cobimetinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Hairy Cell Leukemia::Diagnostic:Supports:Positive:Somatic Mutation|12:4:C:Papillary Thyroid Carcinoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Non-small Cell Lung Carcinoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Anaplastic Thyroid Carcinoma:Dabrafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:4:B:Colorectal Cancer::Prognostic:Supports:Negative:Somatic Mutation|12:4:B:Papillary Thyroid Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|12:5:B:Papillary Thyroid Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|12:5:B:Papillary Thyroid Carcinoma::Diagnostic:Supports:Positive:Somatic Mutation|12:5:B:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:5:A:Skin Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:5:B:Melanoma:Dabrafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:5:B:Melanoma:Trametinib,Dabrafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|12:5:B:Colorectal Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|12:5:B:Papillary Thyroid Carcinoma::Prognostic:Does Not Support:Poor Outcome:Somatic Mutation
7	140453136	140453137	AC	TT	BRAF	V600K	563:0:B:Melanoma:Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|563:0:B:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|563:0:B:Melanoma:Dabrafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|563:3:C:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|563:3:B:Skin Melanoma:Dabrafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|563:4:B:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|563:4:B:Melanoma:Dabrafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|563:4:B:Melanoma:Trametinib,Dabrafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453145	140453145	A	C	BRAF	L597R	288:2:D:Skin Melanoma:Vemurafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|288:4:C:Melanoma:Vemurafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453145	140453145	A	T	BRAF	L597Q	583:2:D:Skin Melanoma:Vemurafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|583:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|583:3:C:Skin Melanoma:Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453145	140453146	AG	GA	BRAF	L597S	582:2:D:Skin Melanoma:Vemurafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|582:3:C:Skin Melanoma:TAK-733:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453146	140453146	G	C	BRAF	L597V	585:3:C:Skin Melanoma:Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453149	140453149	C	A	BRAF	G596C	694:0:D:Non-small Cell Lung Carcinoma:Dabrafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453149	140453149	C	G	BRAF	G596R	1627:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	140453154	140453154	T	A	BRAF	D594V	580:3:E:Skin Melanoma:Sorafenib,Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453154	140453154	T	C	BRAF	D594G	611:0:C:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|611:1:C:Colorectal Cancer:Panitumumab,Cetuximab:Predictive:Does Not Support:Resistance:Somatic Mutation|611:1:B:Colorectal Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|611:2:B:Colorectal Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|611:3:D:Skin Melanoma:Sorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|611:3:D:Skin Melanoma:U0126:Predictive:Supports:Resistance:
7	140453154	140453154	T	G	BRAF	D594A	579:3:E:Skin Melanoma:MEK Inhibitor,Sorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140453193	140453193	T	C	BRAF	N581S	1186:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	140477794	140477794	A	T	BRAF	L505H	658:3:B:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|658:4:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation
7	140477838	140477855	AGGTGCTGTCACATTCAA	-	BRAF	DEL 485-490	522:3:D:Cancer:LY3009120:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140477859	140477860	TT	CA	BRAF	K483M	581:3:E:Skin Melanoma:Sorafenib,MEK Inhibitor:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140481402	140481402	C	G	BRAF	G469A	992:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	140481402	140481402	C	T	BRAF	G469E	993:3:D:Skin Melanoma:U0126:Predictive:Supports::Somatic Mutation|993:3:D:Skin Melanoma:Sorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
7	140481411	140481411	C	A	BRAF	G466V	2222:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
7	140481417	140481417	C	A	BRAF	G464V	1106:2:C:Cancer:Vemurafenib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
8	38274849	38274849	G	T	FGFR1	N546K	515:2:E:Bone Ewing's Sarcoma:Ponatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	5070053	5070053	-	G	JAK2	Exon 12 splice site insertion	615:4:C:Skin Melanoma:Pembrolizumab:Predictive:Supports:Resistance:Somatic Mutation
9	5070054	5070054	T	G	JAK2	F547 SPLICE SITE MUTATION	1681:0:C:Melanoma:Pembrolizumab:Predictive:Supports:Resistance:Somatic Mutation
9	5073770	5073770	G	T	JAK2	V617F	64:3:D:Polycythemia Vera:TG101348:Predictive:Supports:Sensitivity/Response:Somatic Mutation|64:4:B:Lymphoid Leukemia::Diagnostic:Supports:Negative:Somatic Mutation|64:4:B:Bone Marrow Cancer::Diagnostic:Supports:Positive:Somatic Mutation|64:4:B:Chronic Myeloid Leukemia::Diagnostic:Supports:Positive:Somatic Mutation|64:4:B:Polycythemia Vera:Pegylated IFN-alpha-2a:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	8521481	8521481	C	T	PTPRD	V253I	792:4:C:Bone Ewing's Sarcoma:Cixutumumab,R1507:Predictive:Supports:Sensitivity/Response:Germline Mutation
9	21975017	21975017	C	T	CDKN2A	RS3814960	641:3:B:Esophagus Squamous Cell Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation
9	80409488	80409488	T	G	GNAQ	Q209P	604:2:C:Skin Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|604:3:D:Skin Melanoma:PLX4720:Predictive:Supports:Resistance:Somatic Mutation
9	133738330	133738330	A	G	ABL1	BCR-ABL M244V	1021:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1021:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1021:2:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1021:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1021:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1021:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133738342	133738342	C	G	ABL1	BCR-ABL L248V	1022:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1022:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1022:2:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate,Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|1022:2:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1022:2:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1022:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133738349	133738349	G	A	ABL1	BCR-ABL G250E	1023:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1023:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|1023:1:B:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1023:2:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1023:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1023:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1023:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|1023:3:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1023:3:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1023:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133738356	133738356	G	C	ABL1	Q252H	1024:1:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|1024:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1024:2:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|1024:3:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1024:3:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	133738357	133738357	T	C	ABL1	BCR-ABL Y253H	1025:1:B:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1025:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate,Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1025:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1025:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1025:3:C:Chronic Myeloid Leukemia:Imatinib Mesylate,Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1025:3:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1025:3:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1025:3:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133738358	133738358	A	T	ABL1	Y253F	1026:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1026:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1026:2:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
9	133738363	133738363	G	A	ABL1	BCR-ABL E255K	3:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Resistance:Somatic Mutation|3:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|3:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|3:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|3:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|3:2:D:Chronic Myeloid Leukemia:Dasatinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|3:2:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|3:3:C:Chronic Myeloid Leukemia:Imatinib Mesylate,Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|3:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|3:3:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|3:3:D:Chronic Myeloid Leukemia:Dasatinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|3:4:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation
9	133738364	133738364	A	T	ABL1	BCR-ABL E255V	1173:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|1173:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1173:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1173:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate,Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1173:3:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1173:3:C:Chronic Myeloid Leukemia:Imatinib Mesylate,Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1173:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133747520	133747520	A	G	ABL1	BCR-ABL D276G	1027:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1027:2:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1027:2:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1027:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1027:3:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133747528	133747528	G	A	ABL1	E279K	1526:3:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133747568	133747568	A	T	ABL1	E292V	1183:2:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Resistance:Somatic Mutation
9	133747585	133747585	C	G	ABL1	L298V	1506:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133747588	133747588	G	C	ABL1	BCR-ABL V299L	1231:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|1231:1:B:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1231:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|1231:2:D:Chronic Myeloid Leukemia:Dasatinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1231:2:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|1231:3:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1231:3:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation
9	133747592	133747592	A	G	ABL1	Q300R	1527:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1527:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation
9	133748270	133748270	T	A	ABL1	BCR-ABL F311I	1507:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133748270	133748270	T	C	ABL1	BCR-ABL F311L	1528:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1528:2:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation
9	133748283	133748283	C	T	ABL1	BCR-ABL T315I	2:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|2:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|2:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Resistance:Somatic Mutation|2:2:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|2:2:C:Acute Lymphocytic Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|2:2:D:Chronic Myeloid Leukemia:Dasatinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|2:3:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|2:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|2:3:D:Chronic Myeloid Leukemia:Dasatinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|2:3:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate,Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|2:3:D:Chronic Myeloid Leukemia:Nilotinib,Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|2:4:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|2:4:B:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|2:4:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|2:4:B:Chronic Myeloid Leukemia:Ponatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	133748288	133748288	T	A	ABL1	BCR-ABL F317I	1625:1:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|1625:2:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation
9	133748288	133748288	T	C	ABL1	BCR-ABL F317L	241:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|241:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|241:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|241:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|241:2:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|241:2:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|241:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|241:3:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|241:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|241:3:D:Chronic Myeloid Leukemia:Ponatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|241:3:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|241:3:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|241:5:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|241:5:B:Chronic Myeloid Leukemia:Ponatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	133748288	133748288	T	G	ABL1	BCR-ABL F317V	1525:2:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation|1525:3:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation
9	133748300	133748301	GG	CT	ABL1	G340L	1657:3:D:Non-small Cell Lung Carcinoma:Imatinib Mesylate,Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	133748331	133748331	A	G	ABL1	BCR-ABL N331S	1529:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133748333	133748333	C	T	ABL1	R351W	1656:4:D:Non-small Cell Lung Carcinoma:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1656:5:D:Non-small Cell Lung Carcinoma:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	133748346	133748346	A	G	ABL1	N336S	1640:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1640:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133748391	133748391	T	C	ABL1	BCR-ABL M351T	1029:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1029:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1029:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|1029:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|1029:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1029:3:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1029:3:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1029:4:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133748403	133748403	A	G	ABL1	BCR-ABL E355G	1487:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1487:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1487:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1487:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1487:2:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133748414	133748414	T	A	ABL1	BCR-ABL F359I	1523:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1523:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1523:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133748414	133748414	T	G	ABL1	BCR-ABL F359V	892:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|892:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|892:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|892:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Reduced Sensitivity:Somatic Mutation|892:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|892:2:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|892:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|892:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|892:3:C:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|892:3:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Resistance:Somatic Mutation
9	133748415	133748415	T	G	ABL1	BCR-ABL F359C	1184:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1184:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1184:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate,Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1184:2:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1184:2:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1184:3:C:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1184:3:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133750260	133750260	T	C	ABL1	BCR-ABL L364P	1530:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133750304	133750304	G	A	ABL1	BCR-ABL V379I	1609:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1609:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1609:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation
9	133750319	133750319	C	A	ABL1	L384M	1230:1:D:Chronic Myeloid Leukemia:Nilotinib,Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1230:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Resistance:Somatic Mutation
9	133750328	133750328	T	A	ABL1	BCR-ABL L387M	1488:3:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133750330	133750330	G	C	ABL1	L387F	1232:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Resistance:Somatic Mutation|1232:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1232:2:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Resistance:Somatic Mutation
9	133750356	133750356	A	C	ABL1	BCR-ABL H396P	1531:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate,Nilotinib:Predictive:Supports:Resistance:Somatic Mutation|1531:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133750356	133750356	A	G	ABL1	BCR-ABL H396R	1030:0:C:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1030:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1030:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1030:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Resistance:Somatic Mutation|1030:2:D:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1030:2:D:Chronic Myeloid Leukemia:Imatinib:Predictive:Supports:Resistance:Somatic Mutation|1030:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133750358	133750358	G	C	ABL1	BCR-ABL A397P	1612:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1612:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:
9	133750361	133750361	G	C	ABL1	BCR-ABL G398R	1233:2:D:Chronic Myeloid Leukemia:Dasatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1233:3:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	133750431	133750431	A	G	ABL1	D421G	1532:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133753880	133753880	A	T	ABL1	BCR-ABL E450V	1534:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133753888	133753888	G	A	ABL1	BCR-ABL E453K	1535:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133753888	133753888	G	C	ABL1	BCR-ABL E453Q	1509:2:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133753889	133753889	A	C	ABL1	E453A	1536:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1536:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133753906	133753906	G	A	ABL1	BCR-ABL E459K	2370:1:C:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|2370:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|2370:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133753954	133753955	TG	GT	ABL1	C475V	1639:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1639:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation
9	133755469	133755469	C	G	ABL1	BCR-ABL P480A	1537:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Does Not Support:Resistance:Somatic Mutation
9	133755488	133755488	T	C	ABL1	BCR-ABL F486S	1152:1:C:Chronic Myeloid Leukemia:Imatinib Mesylate:Predictive:Supports:Resistance:Somatic Mutation|1152:1:C:Chronic Myeloid Leukemia:Bosutinib:Predictive:Supports:Resistance:Somatic Mutation|1152:3:B:Chronic Myeloid Leukemia:Dasatinib:Predictive:Does Not Support:Resistance:Somatic Mutation|1152:3:D:Chronic Myeloid Leukemia:Nilotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
9	135771933	135771933	G	A	TSC1	R1062W	714:2:C:Tuberous Sclerosis::Predisposing:Supports:Uncertain Significance:Germline Mutation|714:3:D:Tuberous Sclerosis::Predisposing:Supports:Uncertain Significance:Germline Mutation
9	139390861	139390861	G	TGT	NOTCH1	V2444FS	137:4:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation
9	139391212	139391212	G	A	NOTCH1	R2327W	136:4:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation
9	139391369	139391369	-	A	NOTCH1	S2275FS	138:4:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation
9	139399219	139399219	C	G	NOTCH1	D1642H	135:4:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation
10	43609070	43609070	G	A	RET	C609Y	1260:4:B:Thyroid Medullary Carcinoma::Predisposing:Supports:Pathogenic:Germline Mutation
10	43609950	43609950	C	G	RET	C634W	112:3:D:Thyroid Medullary Carcinoma:Motesanib:Predictive:Supports:Resistance:Somatic Mutation
10	43617416	43617416	T	C	RET	M918T	113:3:B:Thyroid Medullary Carcinoma:Sorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|113:3:D:Thyroid Medullary Carcinoma:AZD1480:Predictive:Supports:Sensitivity/Response:Somatic Mutation|113:3:D:Thyroid Medullary Carcinoma:Motesanib:Predictive:Supports:Resistance:Somatic Mutation|113:4:B:Thyroid Medullary Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|113:5:B:Thyroid Medullary Carcinoma::Diagnostic:Supports:Positive:Somatic Mutation
10	89692904	89692904	C	T	PTEN	R130*	636:2:D:Thyroid Cancer:Perifosine,Temsirolimus:Predictive:Supports:Sensitivity/Response:N/A
10	89711899	89711899	C	T	PTEN	R173C	838:1:E:Endometrial Hyperplasia::Predisposing:Supports:Uncertain Significance:Somatic Mutation|838:3:C:PTEN Hamartoma Tumor Syndrome::Predisposing:Supports:Uncertain Significance:Germline Mutation|838:3:D:Cancer::Predisposing:Supports:Uncertain Significance:N/A
10	89717672	89717672	C	T	PTEN	R233*	110:3:B:Glioblastoma Multiforme::Prognostic:Does Not Support:Poor Outcome:Somatic Mutation|110:4:D:Breast Cancer:MTOR Inhibitors:Predictive:Supports:Sensitivity/Response:Somatic Mutation
10	89720799	89720802	TACT	-	PTEN	V317FS	605:3:D:Skin Melanoma:MK-2206,PD184352:Predictive:Supports:Sensitivity/Response:Somatic Mutation
10	104850745	104850745	T	G	NT5C2	D407A	240:4:D:T-cell Acute Lymphoblastic Leukemia:Nelarabine,Arabinosylguanine:Predictive:Does Not Support:Resistance:Somatic Mutation|240:4:D:T-cell Acute Lymphoblastic Leukemia:6-mercaptopurine,6-thioguanine:Predictive:Supports:Resistance:Somatic Mutation
10	104852955	104852955	C	T	NT5C2	R367Q	238:4:D:T-cell Acute Lymphoblastic Leukemia:6-mercaptopurine,6-thioguanine:Predictive:Supports:Resistance:Somatic Mutation|238:4:D:T-cell Acute Lymphoblastic Leukemia:Arabinosylguanine,Nelarabine:Predictive:Does Not Support:Resistance:Somatic Mutation
10	104852980	104852980	T	G	NT5C2	K359Q	239:4:D:T-cell Acute Lymphoblastic Leukemia:Nelarabine,Arabinosylguanine:Predictive:Does Not Support:Resistance:Somatic Mutation|239:4:B:Acute Lymphocytic Leukemia::Prognostic:Supports:Poor Outcome:Somatic Mutation|239:4:D:T-cell Acute Lymphoblastic Leukemia:6-mercaptopurine,6-thioguanine:Predictive:Supports:Resistance:Somatic Mutation
10	123258034	123258034	A	T	FGFR2	N550K	545:3:D:Endometrial Cancer:PD173074:Predictive:Supports:Sensitivity/Response:Somatic Mutation
10	131265545	131265545	C	T	MGMT	RS16906252	338:3:B:Glioblastoma Multiforme:Temozolomide:Predictive:Supports:Sensitivity/Response:Germline Polymorphism
11	534285	534285	C	T	HRAS	G13D	274:0:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|274:0:C:Skin Squamous Cell Carcinoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|274:3:C:Colorectal Cancer:EGFR Inhibitor:Predictive:Supports:Resistance:Somatic Mutation
11	9599943	9599943	A	G	WEE1	RS3910384	331:3:B:Non-small Cell Lung Carcinoma:PLATINUM,Gemcitabine:Predictive:Supports:Sensitivity/Response:Germline Polymorphism
11	64572092	64572092	C	-	MEN1	FRAMESHIFT TRUNCATION	667:2:C:Thyroid Hurthle Cell Carcinoma::Diagnostic:Supports:Positive:Somatic Mutation
11	67352689	67352689	A	G	GSTP1	I105V	259:4:B:Colorectal Cancer:FolfoxProtocol:Predictive:Supports:Sensitivity/Response:Germline Mutation
11	108196840	108196841	TC	-	ATM	V2288FS*1	243:3:C:Prostate Cancer:Olaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
11	108218044	108218044	A	C	ATM	N2875H	244:3:C:Prostate Cancer:Olaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	21329738	21329738	A	G	SLCO1B1	N130D	778:3:B:Cancer:Methotrexate:Predictive:Supports:Adverse Response:Germline Polymorphism
12	21331549	21331549	T	C	SLCO1B1	RS4149056	777:3:B:Cancer:Methotrexate:Predictive:Supports:Adverse Response:Germline Polymorphism
12	25360224	25360224	A	C	KRAS	RS61764370	254:3:B:Head And Neck Squamous Cell Carcinoma:Cisplatin:Predictive:Supports:Resistance:Germline Polymorphism|254:3:B:Epithelial Ovarian Cancer:Carboplatin,Paclitaxel:Predictive:Supports:Resistance:Germline Polymorphism
12	25378561	25378561	G	A	KRAS	A146V	322:2:C:Non-small Cell Lung Carcinoma:LY2835219:Predictive:Supports:Sensitivity/Response:Somatic Mutation|322:3:D:Colorectal Cancer:BEZ235 (NVP-BEZ235, Dactolisib),Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	25378562	25378562	C	G	KRAS	A146P	905:3:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
12	25378562	25378562	C	T	KRAS	A146T	906:3:B:Colorectal Cancer:FOLFOX4,Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|906:3:D:Colorectal Cancer:Selumetinib (AZD6244),BEZ235:Predictive:Supports:Sensitivity/Response:Somatic Mutation|906:3:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
12	25380275	25380275	T	G	KRAS	Q61H	907:0:C:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
12	25398255	25398255	G	A	KRAS	Q22*	479:2:C:Colon Mucinous Adenocarcinoma:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation
12	25398280	25398281	GC	AA	KRAS	G13V	1517:2:C:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Supports:Resistance:Somatic Mutation
12	25398281	25398281	C	T	KRAS	G13D	81:0:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|81:0:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|81:0:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|81:2:C:Colorectal Cancer:Panitumumab,Cetuximab:Predictive:Does Not Support:Resistance:Somatic Mutation|81:2:C:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|81:2:B:Colorectal Cancer:Cetuximab:Predictive:Does Not Support:Resistance:Somatic Mutation|81:2:D:Colorectal Cancer:Selumetinib (AZD6244),BEZ235:Predictive:Supports:Sensitivity/Response:Somatic Mutation|81:3:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|81:4:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|81:4:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|81:4:B:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
12	25398284	25398284	C	A	KRAS	G12V	425:0:D:Colorectal Cancer:Regorafenib:Predictive:Supports:Resistance:Somatic Mutation|425:0:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|425:1:D:Non-small Cell Lung Carcinoma:PD0332991:Predictive:Supports:Sensitivity/Response:Somatic Mutation|425:1:B:Non-small Cell Lung Carcinoma:Docetaxel,Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Somatic Mutation|425:2:C:Lung Cancer:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|425:2:C:Cancer:Crizotinib:Predictive:Does Not Support:Resistance:Somatic Mutation|425:2:C:Colorectal Cancer:Panitumumab,Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|425:3:D:Colorectal Cancer:Selumetinib (AZD6244),BEZ235:Predictive:Supports:Sensitivity/Response:Somatic Mutation|425:3:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|425:4:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
12	25398284	25398284	C	G	KRAS	G12A	148:0:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|148:2:D:Colorectal Cancer:Regorafenib:Predictive:Supports:Resistance:Somatic Mutation|148:2:D:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|148:2:B:Lung Cancer:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|148:2:C:Colorectal Cancer:Panitumumab,Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|148:2:B:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|148:3:B:Lung Adenocarcinoma:Gefitinib,Erlotinib:Predictive:Supports:Resistance:Somatic Mutation
12	25398284	25398284	C	T	KRAS	G12D	79:0:D:Ovarian Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|79:0:D:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|79:0:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|79:0:B:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|79:0:D:Colorectal Cancer:Regorafenib:Predictive:Supports:Resistance:Somatic Mutation|79:2:C:Hairy Cell Leukemia:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|79:2:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|79:2:B:Lung Cancer:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|79:2:D:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|79:2:C:Colorectal Cancer:Cetuximab,Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|79:2:C:Pancreatic Carcinoma:MK-2206:Predictive:Supports:Sensitivity/Response:Somatic Mutation|79:3:B:Tumor Of Exocrine Pancreas::Prognostic:Supports:Poor Outcome:Somatic Mutation|79:3:D:Colorectal Cancer:BEZ235,Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Somatic Mutation|79:3:C:Colorectal Cancer:Adoptive T-cell Transfer:Predictive:Supports:Sensitivity/Response:Somatic Mutation|79:3:B:Lung Cancer::Diagnostic:Supports:Positive:Somatic Mutation|79:3:B:Colorectal Cancer::Prognostic:Supports:Positive:Somatic Mutation|79:3:B:Pancreatic Ductal Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|79:4:B:Pancreatic Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|79:4:D:Non-small Cell Lung Carcinoma:BEZ235 (NVP-BEZ235, Dactolisib),ARRY-142886:Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	25398285	25398285	C	A	KRAS	G12C	78:0:D:Colorectal Cancer:Regorafenib:Predictive:Supports:Resistance:Somatic Mutation|78:0:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|78:0:B:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|78:0:D:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|78:2:D:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|78:2:B:Lung Cancer::Diagnostic:Supports:Positive:Somatic Mutation|78:2:B:Lung Cancer:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|78:2:D:Colorectal Cancer:Selumetinib (AZD6244),BEZ235:Predictive:Supports:Sensitivity/Response:Somatic Mutation|78:3:B:Colorectal Cancer:Gefitinib,Erlotinib:Predictive:Supports:Resistance:Somatic Mutation|78:3:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Poor Outcome:Somatic Mutation|78:3:D:Cancer:EGFR Inhibitor,ARS-853:Predictive:Supports:Sensitivity/Response:Somatic Mutation|78:3:B:Non-small Cell Lung Carcinoma:Selumetinib (AZD6244),Docetaxel:Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	25398285	25398285	C	G	KRAS	G12R	530:0:D:Colorectal Cancer:Regorafenib:Predictive:Supports:Resistance:Somatic Mutation|530:0:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|530:4:B:Pancreatic Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|530:4:D:Colorectal Cancer:Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
12	25398285	25398285	C	T	KRAS	G12S	913:0:D:Colorectal Cancer:Regorafenib:Predictive:Supports:Resistance:Somatic Mutation|913:0:C:Colorectal Cancer:Panitumumab:Predictive:Supports:Resistance:Somatic Mutation|913:0:B:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation|913:2:C:Colorectal Cancer:Panitumumab,Cetuximab:Predictive:Supports:Resistance:Somatic Mutation|913:2:B:Lung Cancer:Gefitinib:Predictive:Supports:Resistance:Somatic Mutation|913:2:D:Multiple Myeloma:Melphalan:Predictive:Supports:Resistance:Somatic Mutation
12	56478851	56478851	C	G	ERBB3	R103G	702:3:B:Urothelial Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	56478854	56478854	G	A	ERBB3	V104M	701:3:B:Urothelial Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	56481922	56481922	G	A	ERBB3	G284R	703:3:B:Urothelial Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	56491672	56491672	T	C	ERBB3	V855A	781:2:D:Non-small Cell Lung Carcinoma:Afatinib,Pertuzumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	58145431	58145431	G	A	CDK4	R24C	556:1:D:Skin Melanoma:Palbociclib (PD0332991):Predictive:Supports:Sensitivity/Response:Somatic Mutation
12	69202580	69202580	T	G	MDM2	SNP309	495:2:B:Head And Neck Cancer::Prognostic:Supports:Poor Outcome:Germline Polymorphism
12	111884608	111884608	T	C	SH2B3	RS3184504	699:2:B:Colorectal Cancer::Predisposing:Supports:Positive:Germline Polymorphism
13	28592641	28592641	T	A	FLT3	D835V	1302:0:C:Acute Myeloid Leukemia:Sunitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1302:2:D:Acute Myeloid Leukemia:SU11248,Cytarabine:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1302:2:D:Acute Myeloid Leukemia:Daunorubicin,SU11248:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1302:3:D:Acute Myeloid Leukemia:MLN518:Predictive:Supports:Resistance:Somatic Mutation|1302:3:D:Acute Myeloid Leukemia:AS602868,AG1296:Predictive:Supports:Sensitivity/Response:Somatic Mutation|1302:3:D:Acute Myeloid Leukemia:SU11248:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|1302:5:D:Acute Myeloid Leukemia:Quizartinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation
13	28592642	28592642	C	A	FLT3	D835	437:3:D:Acute Myeloid Leukemia:Quizartinib (AC220),Ponatinib:Predictive:Supports:Resistance:Somatic Mutation|437:3:D:Acute Myeloid Leukemia:SU5614:Predictive:Supports:Resistance:Somatic Mutation|437:4:B:Acute Myeloid Leukemia:Quizartinib (AC220),Sorafenib:Predictive:Supports:Resistance:Somatic Mutation|437:4:B:Acute Myeloid Leukemia:Sorafenib:Predictive:Supports:Resistance:Somatic Mutation
13	28592642	28592642	C	A	FLT3	TKD MUTATION	56:3:B:Acute Myeloid Leukemia::Diagnostic:Does Not Support:Positive:Somatic Mutation|56:3:B:Acute Myeloid Leukemia:Midostaurin:Predictive:Supports:Sensitivity/Response:Somatic Mutation|56:3:B:Acute Myeloid Leukemia::Prognostic:Does Not Support:N/A:Somatic Mutation|56:3:B:Acute Myeloid Leukemia::Prognostic:Supports:Better Outcome:Somatic Mutation|56:4:B:Acute Myeloid Leukemia::Prognostic:Supports:Poor Outcome:Somatic Mutation|56:4:B:Acute Myeloid Leukemia:Sorafenib:Predictive:Supports:Resistance:Somatic Mutation
13	28592642	28592642	C	G	FLT3	D835H	612:3:C:Acute Myeloid Leukemia:Sorafenib:Predictive:Supports:Resistance:Somatic Mutation
13	28592642	28592642	C	G/A	FLT3	D835H/Y	613:1:D:Acute Myeloid Leukemia:Sorafenib:Predictive:Supports:Resistance:Somatic Mutation
13	28624294	28624294	G	A	FLT3	T227M	540:3:B:Renal Cell Carcinoma:Sunitinib:Predictive:Supports:Adverse Response:Germline Polymorphism
13	32890599	32890599	T	G	BRCA2	M1R	1247:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
13	32890600	32890600	G	T	BRCA2	M1I	1248:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
13	32900287	32900287	G	A	BRCA2	V159M	1249:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
13	32900751	32900751	G	A	BRCA2	V211I	1251:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
13	32900751	32900751	G	C	BRCA2	V211L	1250:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
13	32921033	32921033	G	A	BRCA2	R2336H	1253:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
13	32921033	32921033	G	C	BRCA2	R2336P	1252:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
13	32968854	32968854	C	A	BRCA2	D3095E	661:1:C:Breast Cancer::Diagnostic:Supports:Positive:Germline Mutation
13	49033946	49033946	-	A	RB1	M695FS*26	638:2:D:Estrogen-receptor Positive Breast Cancer:Palbociclib (PD0332991):Predictive:Supports:Resistance:Somatic Mutation
13	103498198	103498199	A	G	ERCC5	RS751402	255:3:B:Parietal Lobe Ependymoma::Prognostic:Supports:Poor Outcome:Germline Polymorphism
14	62213848	62213848	T	C	HIF1A	3' UTR Polymorphism	433:2:B:Pancreatic Adenocarcinoma::Prognostic:Supports:Poor Outcome:Germline Polymorphism
14	65453063	65453063	G	C	FNTB	RS11623866	332:2:B:Ovarian Cancer:Lonafarnib:Predictive:Supports:Resistance:Germline Polymorphism
14	105243048	105243048	G	T	AKT1	Q79K	169:0:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|169:4:C:Melanoma:Dabrafenib:Predictive:Supports:Resistance:Somatic Mutation|169:4:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation
14	105246551	105246551	C	T	AKT1	E17K	4:0:D:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation|4:2:D:Melanoma:GSK2141795:Predictive:Supports:Sensitivity/Response:Somatic Mutation|4:3:D:Breast Cancer:MK-2206:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|4:3:C:Breast Cancer:AZD5363:Predictive:Supports:Sensitivity/Response:Somatic Mutation|4:4:B:Cancer:AZD-5363:Predictive:Supports:Sensitivity/Response:Somatic Mutation
15	45003786	45003789	TCTT	-	B2M	S14FS	616:3:C:Skin Melanoma:Pembrolizumab:Predictive:Supports:Resistance:Somatic Mutation
15	66727449	66727463	CCAGAAGCAGAAGGT	-	MAP2K1	Q56_V60del	655:4:C:Ovarian Serous Carcinoma:Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Somatic Mutation
15	66727451	66727451	A	C	MAP2K1	Q56P	83:3:D:Melanoma:Selumetinib (AZD6244):Predictive:Supports:Resistance:Somatic Mutation
15	66727455	66727455	G	T	MAP2K1	K57N	1272:2:D:Lung Adenocarcinoma:Selumetinib (AZD6244):Predictive:Supports:Sensitivity/Response:Somatic Mutation|1272:3:C:Lung Adenocarcinoma::Diagnostic:Supports:Positive:Somatic Mutation
15	66729154	66729154	G	C	MAP2K1	C121S	627:4:C:Melanoma:Vemurafenib:Predictive:Supports:Resistance:Somatic Mutation
15	66729162	66729162	C	T	MAP2K1	P124S	82:3:D:Melanoma:Selumetinib (AZD6244):Predictive:Supports:Resistance:Somatic Mutation
15	74315213	74315213	C	T	PML	PML-RARA A216V	462:4:C:Acute Promyelocytic Leukemia:All-trans Retinoic Acid:Predictive:Supports:Resistance:Somatic Mutation
15	74315219	74315219	T	C	PML	PML-RARA L218P	463:3:C:Acute Promyelocytic Leukemia:All-trans Retinoic Acid:Predictive:Supports:Resistance:Somatic Mutation
15	88476265	88476265	C	T	NTRK3	ETV6-NTRK3 G623R	805:4:C:Breast Cancer:Entrectinib:Predictive:Supports:Resistance:Somatic Mutation
15	90631838	90631838	C	T	IDH2	R172K	63:2:B:Myelodysplastic Syndrome::Prognostic:Does Not Support:N/A:Somatic Mutation|63:2:B:Acute Myeloid Leukemia::Prognostic:Does Not Support:N/A:Somatic Mutation|63:3:B:Acute Myeloid Leukemia::Prognostic:Supports:Poor Outcome:Somatic Mutation
16	2130300	2130300	C	T	TSC2	Q1178*	469:5:C:Thyroid Carcinoma:Everolimus:Predictive:Supports:Sensitivity/Response:Somatic Mutation
16	69745145	69745145	G	A	NQO1	P187S	402:2:D:Lung Cancer:Amrubicin:Predictive:Supports:Sensitivity/Response:Germline Polymorphism
17	7577093	7577093	C	A	TP53	R282L	1108:0:C:Stomach Carcinoma:EAP Protocol:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	7577120	7577120	C	A	TP53	R273L	918:0:C:Ovarian Cancer:Cisplatin,Carboplatin:Predictive:Supports:Resistance:Somatic Mutation
17	7577120	7577120	C	T	TP53	R273H	122:3:B:Breast Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|122:4:D:Cancer:AMGMDS3:Predictive:Supports:Resistance:Somatic Mutation
17	7577121	7577121	G	A	TP53	R273C	121:3:C:Stomach Carcinoma:Cisplatin,Mitomycin,Etoposide:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|121:3:B:Breast Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|121:4:D:Cancer:AMGMDS3:Predictive:Supports:Resistance:Somatic Mutation
17	7577535	7577535	C	G	TP53	R249	119:3:B:Breast Cancer:Doxorubicin:Predictive:Supports:Sensitivity/Response:Somatic Mutation|119:3:B:Breast Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation
17	7577538	7577538	C	T	TP53	R248Q	117:3:B:Breast Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|117:4:D:Cancer:AMGMDS3:Predictive:Supports:Resistance:Somatic Mutation
17	7577539	7577539	G	A	TP53	R248W	118:3:B:Breast Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|118:4:D:Cancer:AMGMDS3:Predictive:Supports:Resistance:Somatic Mutation
17	7577580	7577580	T	C	TP53	Y234C	1068:0:C:Ovarian Cancer:Carboplatin,Cisplatin:Predictive:Supports:Resistance:Somatic Mutation
17	7578190	7578190	T	C	TP53	Y220C	922:0:C:Stomach Carcinoma:EAP Protocol:Predictive:Supports:Sensitivity/Response:Somatic Mutation|922:4:D:Cancer:AMGMDS3:Predictive:Supports:Resistance:Somatic Mutation
17	7578211	7578211	C	G	TP53	R213P	1109:0:C:Stomach Carcinoma:EAP Protocol:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	7578406	7578406	C	T	TP53	R175H	116:0:C:Stomach Carcinoma:EAP Protocol:Predictive:Supports:Sensitivity/Response:Somatic Mutation|116:3:D:Breast Cancer:Doxorubicin:Predictive:Supports:Sensitivity/Response:Somatic Mutation|116:3:B:Breast Cancer::Prognostic:Supports:Poor Outcome:Somatic Mutation|116:4:D:Cancer:AMGMDS3:Predictive:Supports:Resistance:Somatic Mutation
17	7578461	7578461	C	A	TP53	V157F	1092:4:D:Cancer:AMGMDS3:Predictive:Supports:Resistance:Somatic Mutation
17	7579472	7579472	G	C	TP53	P72R	531:2:B:Cervical Cancer::Prognostic:Does Not Support:Poor Outcome:Germline Polymorphism|531:3:B:Lung Carcinoma::Prognostic:Does Not Support:Poor Outcome:Germline Polymorphism|531:4:B:Breast Cancer::Predisposing:Does Not Support:Positive:Germline Polymorphism
17	7579548	7579548	G	A	TP53	P47S	504:2:E:Cancer:Cisplatin:Predictive:Supports:Resistance:Germline Polymorphism
17	33433425	33433425	G	A	RAD51D	R186*	471:2:C:Breast Cancer::Predisposing:Supports::Germline Mutation
17	37868205	37868205	G	C	ERBB2	G309A	38:5:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37879658	37879658	G	A	ERBB2	R678Q	42:5:D:Breast Cancer:Neratinib,Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880219	37880233	TTGAGGGAAAACACA	-	ERBB2	DEL 755-759	37:5:D:Breast Cancer:Lapatinib,Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880220	37880220	T	C	ERBB2	L755S	39:4:D:Colon Cancer:Trastuzumab,Neratinib,Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|39:5:D:Breast Cancer:Lapatinib:Predictive:Supports:Resistance:Somatic Mutation|39:5:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880220	37880220	T	G	ERBB2	L755W	40:5:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880261	37880261	G	C	ERBB2	D769H	35:4:D:Breast Cancer:Lapatinib,Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880261	37880261	G	T	ERBB2	D769Y	36:4:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880989	37880989	T	C	ERBB2	V773A	872:3:D:Head And Neck Squamous Cell Carcinoma:Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880991	37880991	A	TGGCTGG	ERBB2	M774DELINSWLV	818:3:C:Non-small Cell Lung Carcinoma:Dacomitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880996	37880996	-	TACGTGATGGCT	ERBB2	Y772_A775DUP	414:2:B:Non-small Cell Lung Carcinoma:Dacomitinib:Predictive:Does Not Support:Sensitivity/Response:Somatic Mutation|414:3:C:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|414:3:C:Lung Adenocarcinoma:Trastuzumab Emtansine:Predictive:Supports:Sensitivity/Response:Somatic Mutation|414:3:D:Non-small Cell Lung Carcinoma:Afatinib,Rapamycin (Sirolimus):Predictive:Supports:Sensitivity/Response:Somatic Mutation|414:4:D:Lung Carcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|414:4:C:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37880997	37880998	GG	CT	ERBB2	G776L	816:3:C:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881000	37881000	G	T	ERBB2	V777L	44:4:D:Colon Cancer:Neratinib,Lapatinib,Trastuzumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|44:5:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881011	37881011	-	GGCTCCCCA	ERBB2	G778_P780DUP	817:3:C:Lung Adenocarcinoma:Afatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|817:3:C:Non-small Cell Lung Carcinoma:Dacomitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881011	37881011	-	GGCTCCCCA	ERBB2	P780INS	41:3:C:Lung Adenocarcinoma:Dacomitinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|41:5:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881332	37881332	G	A	ERBB2	V842I	45:4:D:Colon Cancer:Neratinib,Lapatinib,Trastuzumab:Predictive:Supports:Sensitivity/Response:Somatic Mutation|45:5:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881378	37881378	A	G	ERBB2	N857S	873:3:D:Ovarian Cancer:Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881392	37881392	A	G	ERBB2	T862A	871:3:D:Stomach Carcinoma:Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881404	37881404	C	A	ERBB2	L866M	496:4:D:Colon Cancer:Trastuzumab,Lapatinib,Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881440	37881440	C	T	ERBB2	H878Y	874:3:D:Hepatocellular Carcinoma:Lapatinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	37881616	37881616	C	T	ERBB2	R896C	43:5:D:Breast Cancer:Neratinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41199682	41199682	C	T	BRCA1	W1815X	1555:0:D:Ovarian Cancer:Olaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41219625	41219625	C	T	BRCA1	D1692N	1244:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41226348	41226348	C	T	BRCA1	E1559K	1243:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41228505	41228505	C	A	BRCA1	R1495M	1242:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41228590	41228590	G	A	BRCA1	Q1467*	1246:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41234451	41234451	G	A	BRCA1	R1443*	1245:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41244645	41244645	-	GA	BRCA1	P968FS	477:4:C:Ovarian Cancer::Predisposing:Supports:Pathogenic:Germline Mutation|477:4:C:Breast Cancer::Predisposing:Supports:Likely Pathogenic:Germline Mutation
17	41258473	41258473	C	T	BRCA1	R71K	1241:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41258474	41258474	T	C	BRCA1	R71G	1240:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41258494	41258494	C	T	BRCA1	C64Y	1239:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41258504	41258504	A	C	BRCA1	C61G	1238:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41276111	41276111	C	A	BRCA1	M1I	1237:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	41276113	41276113	T	C	BRCA1	M1V	1236:0:C:Ovarian Cancer:Rucaparib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
17	46805705	46805705	C	T	HOXB13	G84E	772:4:B:Prostate Cancer::Predisposing:Supports:Uncertain Significance:Germline Polymorphism|772:4:B:Prostate Cancer::Predisposing:Supports:Positive:Germline Mutation
18	657646	657646	C	T	TYMS	RS34743033	779:3:B:Cancer:Methotrexate:Predictive:Supports:Adverse Response:Germline Polymorphism
18	42531913	42531913	G	A	SETBP1	G870S	351:3:D:Chronic Myeloid Leukemia::Prognostic:Supports:Poor Outcome:Somatic Mutation
19	1220489	1220489	C	A	STK11	D194E	634:2:C:Pancreatic Cancer:Everolimus:Predictive:Supports:Sensitivity/Response:Germline Mutation
19	7975157	7975157	G	A	MAP2K7	E116K	566:5:B:Lung Cancer::Prognostic:Supports:Poor Outcome:Germline Polymorphism
19	44055726	44055726	T	C	XRCC1	Q399R	261:4:B:Non-small Cell Lung Carcinoma::Prognostic:Supports:Better Outcome:Germline Mutation|261:4:B:Cervical Cancer:Cisplatin,Carboplatin:Predictive:Supports:Sensitivity/Response:Germline Mutation
19	44057574	44057574	G	A	XRCC1	R194W	249:4:B:Non-small Cell Lung Carcinoma:Gemcitabine,Vinorelbine,Docetaxel:Predictive:Supports:Sensitivity/Response:Germline Mutation
19	45854919	45854919	T	G	ERCC2	K751Q	264:3:B:Non-small Cell Lung Carcinoma:Paclitaxel,Carboplatin:Predictive:Supports:Sensitivity/Response:Germline Mutation|264:4:B:Osteosarcoma:Cisplatin:Predictive:Supports:Resistance:Germline Mutation
19	49377242	49377242	G	C	PPP1R15A	RS557806	548:1:B:Colorectal Cancer:Bevacizumab,FOLFIRI Regimen:Predictive:Supports:Sensitivity/Response:Germline Polymorphism
20	57428713	57428713	T	C	GNAS	T393C	877:2:B:Non-small Cell Lung Carcinoma:Gefitinib,Erlotinib:Predictive:Supports:Resistance:Germline Polymorphism|877:3:B:Intrahepatic Cholangiocarcinoma::Prognostic:Supports:Poor Outcome:Germline Polymorphism|877:4:B:Clear Cell Renal Cell Carcinoma::Prognostic:Supports:Better Outcome:Germline Polymorphism|877:4:B:Esophageal Cancer:5-fluorouracil,Cisplatin:Predictive:Supports:Resistance:Germline Polymorphism|877:4:B:Bladder Urothelial Carcinoma::Prognostic:Supports:Better Outcome:Germline Polymorphism|877:4:B:Colorectal Cancer::Prognostic:Supports:Better Outcome:Germline Polymorphism|877:4:B:Breast Carcinoma::Prognostic:Supports:Poor Outcome:Germline Polymorphism|877:4:B:Melanoma::Prognostic:Supports:Better Outcome:Germline Polymorphism|877:4:B:Chronic Lymphocytic Leukemia::Prognostic:Supports:Better Outcome:Germline Polymorphism
20	57484420	57484420	C	T	GNAS	R201C	826:2:C:Colorectal Cancer:Vemurafenib,Cetuximab,Irinotecan:Predictive:Supports:Resistance:Somatic Mutation
21	36171704	36171704	G	T	RUNX1	Y260*	803:3:C:Acute Myeloid Leukemia::Predisposing:Supports:Positive:Germline Mutation
21	36231792	36231792	C	A	RUNX1	D198Y	806:3:C:Acute Myeloid Leukemia::Predisposing:Supports:Uncertain Significance:Germline Mutation
21	36252913	36252920	GCTGCGGT	-	RUNX1	T148HFSX9	810:2:C:Acute Myeloid Leukemia::Predisposing:Supports:Uncertain Significance:Germline Mutation
21	36252962	36252962	C	G	RUNX1	A107P	807:5:C:Acute Myeloid Leukemia::Predisposing:Supports:Positive:Germline Mutation
21	36259163	36259163	T	C	RUNX1	K83E	802:4:C:Acute Myeloid Leukemia::Predisposing:Supports:Positive:Germline Mutation
21	40191638	40191638	A	G	ETS2	RS461155	445:2:B:Non-small Cell Lung Carcinoma:Cisplatin,Paclitaxel:Predictive:Supports:Sensitivity/Response:Germline Polymorphism
21	44514777	44514777	T	G	U2AF1	Q157P/R	127:2:B:Acute Myeloid Leukemia::Prognostic:Does Not Support:N/A:Somatic Mutation|127:2:B:Myelodysplastic Syndrome::Prognostic:Does Not Support:N/A:Somatic Mutation|127:3:B:Myelodysplastic Syndrome::Prognostic:Supports:Poor Outcome:Somatic Mutation|127:3:B:Acute Myeloid Leukemia::Diagnostic:Does Not Support:Positive:Somatic Mutation
21	44524456	44524456	G	A	U2AF1	S34Y/F	128:2:B:Acute Myeloid Leukemia::Prognostic:Does Not Support:N/A:Somatic Mutation|128:3:B:Myelodysplastic Syndrome::Prognostic:Supports:Poor Outcome:Somatic Mutation|128:3:B:Acute Myeloid Leukemia::Diagnostic:Does Not Support:Positive:Somatic Mutation
22	22127164	22127164	C	T	MAPK1	E322K	320:4:C:Head And Neck Squamous Cell Carcinoma:Erlotinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
22	29091857	29091857	G	-	CHEK2	1100DELC	785:3:B:Prostate Cancer::Predisposing:Supports:Positive:Germline Mutation
22	29121087	29121087	A	G	CHEK2	I157T	787:3:B:Prostate Cancer::Predisposing:Supports:Uncertain Significance:Germline Mutation
22	30051593	30051593	-	T	NF2	Y177FS	245:3:C:Peritoneal Mesothelioma:Carboplatin,Cisplatin:Predictive:Supports:Resistance:Somatic Mutation
X	47426121	47426121	C	G	ARAF	S214C	10:2:C:Non-small Cell Lung Carcinoma:Sorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|10:3:D:Non-small Cell Lung Carcinoma:Trametinib:Predictive:Supports:Sensitivity/Response:Somatic Mutation|10:3:D:Non-small Cell Lung Carcinoma:Sorafenib:Predictive:Supports:Sensitivity/Response:Somatic Mutation
X	47429340	47429340	T	A	ARAF	S490T	825:1:C:Colorectal Cancer:Vemurafenib,Irinotecan,Cetuximab:Predictive:Supports:Resistance:Somatic Mutation
X	66943549	66943549	T	C	AR	F877L	175:4:D:Prostate Cancer:Enzalutamide,ARN-509:Predictive:Supports:Resistance:Somatic Mutation
X	100611165	100611165	A	T	BTK	C481S	168:4:B:Chronic Lymphocytic Leukemia:Ibrutinib:Predictive:Supports:Resistance:Somatic Mutation
X	100613633	100613633	T	C	BTK	T316A	870:4:C:Chronic Lymphocytic Leukemia:Ibrutinib:Predictive:Supports:Resistance:Somatic Mutation
